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I. Introduction 
I.1. Multiple Sclerosis 
On the occasion of the 150th anniversary of the first depiction of Multiple Sclerosis (MS) in 
1988, Alastair Compston published a highly worthwhile article assessing historical cases and 
adding his conclusions about who first described the characteristic lesions (Compston, 1988). 
Today, close to its 180th anniversary, the disease is still not completely understood. MS is 
the most common inflammatory disease of the central nervous system (CNS) and it affects 
the female population more strongly, approaching a ratio of 3:1 (Compston & Coles, 2008). 
Four clinical courses have been described for MS (Lublin et al., 2014 (latest revision); 
Ransohoff et al., 2015). The relapsing remitting course (RRMS) is the most common form 
(about 85%) and is described by acute, symptomatic episodes followed by complete or 
partial remission. This course is often followed by a secondary progressive phase (SPMS), 
characterised by a gradual increase in symptom severity, while acute episodes occur less 
frequently. Primary progressive MS (PPMS) is diagnosed in only a fraction of patients (less 
than 10%) and during its course symptoms chronically worsen in the absence of acute 
episodes. Lastly, the diagnosis of clinically isolated syndrome (CIS) describes patients that 
present with an isolated acute episode, which cannot yet be attributed to MS due to a lack 
of dissemination in time. However, many (30-70%) CIS patients are later diagnosed with MS 
(Miller et al., 2005). 
 
I.1.1. Aetiology 
The aetiology of MS is undoubtedly complex and there have been implications for a large 
variety of contributing factors. Arguing for a pronounced genetic component, the MS 
concordance rate was shown to be 25% between monozygotic twins (Willer et al., 2003). 
Genome-wide association studies (GWAS) have implicated the human leukocyte antigen 
alleles as a prominent risk factor. Amongst other susceptibility loci, T-helper cell 
differentiation genes have been identified (International Multiple Sclerosis Genetics 
Consortium et al., 2007, 2011). However, despite their sibling’s affliction, the majority of 
monozygotic twins do not develop MS. Therefore, genetics cannot be the sole influencing 
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factor. Among the non-genetic risk factors that have been identified are viral infection, 
smoking, Vitamin D deficiency and traumatic head injury at young age (Marrie, 2004; 
Montgomery et al., 2017). The identification of these risk factors, GWAS data and the work 
on MS animal models (most prominently experimental autoimmune encephalomyelitis, EAE, 
see page 4), have led to the identification of MS as an autoimmune disease. In EAE, CD4+ T 
cells have been identified as the mediators of disease induction (Ben-Nun et al., 1981) and 
the human T-cell repertoire is known to host potentially auto-reactive CD4+ T helper cells 
(Martin et al., 1992; O’Connor et al., 2001). Further, inflammatory infiltrates have been 
identified in all MS lesion types (Lucchinetti et al., 2000). Subsequently, targeting immune 
cells has become a successful approach in MS therapy (Hohlfeld & Wekerle, 2004). Two 
hypotheses have been developed to explain how the immune system could be primed 
against self-antigens (see also chapter I.2). Pathogens have been proposed to yield antigens 
that resemble CNS self-antigens and could incite cross-reactions (molecular mimicry). 
Indeed, it has been shown that human T cell clones specific for MBP can be activated by 
viral peptides (Wucherpfennig & Strominger, 1995). Alternatively, Wilkin’s primary lesion 
hypothesis argues that self-antigens could be presented to immune cells as a consequence 
of debris clearing, following a traumatic event inside the CNS. The identification of head 
trauma mentioned above argues in support of this hypothesis (Montgomery et al., 2017). 
 
I.1.2. Grey matter pathology in MS 
White matter lesions are an important hallmark of MS development and for most of the 20th 
century MS was therefore considered a typical white matter disease. Although already 
described in the late 19th century (e.g. Dejerine, 1884; Brauer, 1898), grey matter pathology 
only recently re-entered the spotlight of MS research (Kidd et al., 1999). Symptomatic for 
the ignorance with which it was met during the last century by many in the field of MS 
research, a highly cited review by Compston and Coles only mentions grey matter pathology 
on a side note (Compston & Coles, 2008; 687 citations on PubMed as of 21.12.17). It has 
been argued comprehensibly that this negligence could mainly be attributed to insufficient 
power of the available diagnostic tools (Figure 1; Geurts et al., 2012). With the advent of 
new, high-powered devices for Magnetic Resonance Imaging (MRI) and improved 
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immunohistochemistry methods, the research into MS grey matter pathology has 
experienced an upsurge. Demyelination of the cortex has meanwhile been shown to be very 
prominent, in extreme cases reaching 70% (Kutzelnigg et al., 2005) and cortical lesions have 
been found in 60-80% of multiple sclerosis patients (Hulst & Geurts, 2011). Meningeal 
inflammation and the associated lesions have been linked to neuronal loss and the 
progression of clinical decline in (primary and secondary) progressive MS patients (Bjartmar 
et al., 2003; Howell et al., 2011; Choi et al., 2012). Likewise, grey matter pathology has been 
shown to correlate more strongly with clinical disability than white matter pathology 
(Schlaeger et al., 2014; Steenwijk et al., 2016). It is very likely that grey matter pathology is 
not exclusively consequential of white matter pathology, as grey matter lesions can be 
found already in the early stages of MS, were they have again been strongly associated with 
meningeal inflammation (Bjartmar et al., 2000; Wegner et al., 2006; Lucchinetti et al., 2011). 
Neurodegenerative events can also be evident already at the time of diagnosis (Barkhof et 
al., 2009). For example, cortical atrophy is detectable in early RRMS patients (Chard et al., 
2002). Therefore it becomes imperative to develop animal models of autoimmune grey 
matter pathology in order to allow us to understand and hopefully one day counteract 
cognitive decline in MS patients. 
 
Figure 1: Timeline of developments in grey matter imaging and pathology in multiple sclerosis 
MS=multiple sclerosis. GM=grey matter. WM=white matter. NAA=N-acetyl aspartate. DIR=double inversion 
recovery. Adapted from Geurts et al., 2012. 
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I.2. Experimental Autoimmune Encephalomyelitis - EAE 
As mentioned above, EAE is the prototypic animal model for many aspects of MS. Its 
development into a proper model started in the 1930s when Thomas Rivers injected rhesus 
monkeys with rabbit CNS homogenate, tracing perivascular demyelinating lesions back to an 
immune response against the CNS matter (Rivers et al., 1933). It has since been refined and 
established in a broad variety of animals reaching from non-human primates to rodents. In 
rodents, the disease is characterized clinically by an ascending paralysis and pathologically 
by CNS inflammation caused by the infiltration of auto-reactive immune cells (T cells and 
monocytes) into the CNS. Classical (myelin) active EAE (aEAE), as it is used today, is based on 
an active immunization with myelin proteins or peptides (the most common are myelin 
basic protein (MBP), myelin oligodendrocyte protein (MOG) and proteolipid protein (PLP)) 
or CSF homogenate, both together with an immuno-stimulant, for example Complete 
Freund’s Adjuvant (CFA), a mineral oil emulsion containing heat-inactivated Mycobacterium 
tuberculosis.  
Based on the EAE model, the three-compartment model of EAE and MS was proposed 
(Figure 2; ’t Hart et al., 2008, 2009). According to this model, the peripheral lymph nodes 
(afferent compartment) contain potentially auto-reactive T (and B) cells. In EAE, 
autoreactive T cells are induced via immunization with an antigen, while in MS their 
induction might result from an infection (molecular mimicry) or take place in the draining 
compartment after the occurrence of a primary lesion inside the CNS (Wilkin’s primary 
lesion hypothesis). After overcoming the BBB, in the target compartment, the effector cells 
recognize their cognate antigen through interaction with local antigen presenting cells 
(APCs), triggering an inflammatory cascade that causes local damage. When the resultant 
debris is cleared to the draining lymph nodes (draining compartment) and presented by 
local APCs, the generation of new autoreactive T cells is triggered. The circle is closed when 
these cells are released into the afferent compartment, where they in turn either dampen 
or aggravate the ongoing autoimmune process. 
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The second method of EAE induction is via passive-transfer (ptEAE; Paterson, 1960). Here, T 
cells are primed against specific CNS antigens by active immunization, isolated from draining 
lymph nodes, cultured and subsequently transferred into recipient animals. Owing to this 
approach, CD4+ T cells were originally identified as the culprits of EAE (Ben-Nun et al., 1981). 
By in vitro manipulation, cultured T cells can be virally transduced to express fluorescent 
proteins (Flügel et al., 1999). This labelling introduces the possibility of tracking specific cells 
on their way to and inside the CNS. After i.v. injection, MBP-specific T cells (TMBP cells) are 
not able to directly enter the CNS. Instead, they accumulate in spleen and lung, where their 
 
Figure 2: Three-compartment model for the pathogenesis of EAE and MS. 
(a) The afferent compartment (blue) contains autoreactive T-cells. In the EAE model, these are actively 
induced by immunization with antigen (Ag) emulsified in complete Freund’s adjuvant (CFA) (red box); 
whereas in MS, the presumed trigger is infection with an unidentified pathogen. (b) These T cells collect in 
the spleen before migrating to the target compartment (pink), where they are engaged in cognate 
interactions with local APCs. The resulting cascade of pathophysiological reactions leads to injury. (c) Tissue 
debris is cleared from the CNS and emerges within APCs located in the CNS draining compartment (yellow), 
comprising the cervical and lumbar lymph nodes and spleen. This leads to the activation of new autoreactive 
T-cell specificities. When released into the afferent compartment, the activated T cells can either mitigate or 
exacerbate the ongoing autoimmune reaction. Adapted from ‘t Hart et al. 2009.  
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phenotype is changed to a migratory profile. This reprogramming consists of an 
upregulation of chemokines and adhesion molecules (e.g. CXCR3 and Ninurin-1) and a 
downregulation of activation markers (IFNγ, IL-17, CD25, OX40) and allows the T cells to 
pass the BBB (Flügel et al., 2001; Odoardi et al., 2012). Before infiltrating the CNS, TMBP cells 
scan the inside wall of leptomeningeal blood vessels prior to extravasation.  
 
I.2.1. T-cell entry into the CNS 
In order to enter the CNS, T cells (and other immune cells) must pass the BBB. Among the 
proposed sites of this entry are the blood-leptomeningeal barrier, the BBB inside CNS 
parenchymal vessels and the blood-CSF-barrier in the choroid plexus (Reboldi et al., 2009; 
Ransohoff & Engelhardt, 2012; Schläger et al., 2016). Independently of entry route, 
leukocyte adhesion to the CNS vasculature is a prerequisite for extravasation and consists of 
a multi-step process, governed by the interaction of signalling and adhesion molecules of 
leukocytes and endothelial cells of the blood vessels. The first step of this process, rolling of 
leukocytes on the vessel wall, is signified by transient interactions between selectins on the 
vascular endothelial cells and their ligands on the leukocytes, drastically reducing their 
speed. This process has further been shown to be mediated by the interaction of integrins 
VLA-4 (Very Late Antigen-4, alternatively known as α4β1) and LPAM-1 (lymphocyte Peyer's 
patch adhesion molecule 1) on leukocytes and adhesion molecules on the vascular side 
(vascular cell adhesion molecule (VCAM) and mucosal vascular addressin cell-adhesion 
molecule 1 (MADCAM1)). The next step, leukocyte arrest and crawling, is triggered by the 
binding of chemokines presented by vascular endothelial cells to G-protein coupled 
receptors on the leukocyte surface. This results in an increase in integrin-affinity (VLA-4 and 
lymphocyte function-associated antigen-1 (LFA-1)) to their endothelial ligands (VCAM and 
intracellular adhesion molecules (ICAMs)), thus facilitating intravascular leukocyte crawling 
(Ley et al., 2007; Bartholomäus et al., 2009). Of note, the crucial step in this adhesion 
cascade seems to be VLA-4-dependent, as treatment with VLA-4-blocking antibody has been 
effective in inhibiting TMBP-cell adhesion in spinal cord (SC) leptomeningeal vessels and EAE-
development in the Lewis rat; in the human disease, the α4-blocker Natalizumab is 
efficacious in the treatment of RRMS (Bartholomäus et al., 2009; Goldenberg, 2012). The 
Introduction  7 
CCR6-CCL20 (Chemokine C-C receptor 6 and -ligand 20) axis is suggested to mediate Th17-
cell entry into the brain, while the entry of Th1 cells into the SC via the meninges is 
proposed to be mediated by CXCR3 (Chemokine C-X-C receptor 3) and VLA-4 (Stromnes et 
al., 2008; Reboldi et al., 2009; Rothhammer et al., 2016). In the Lewis rat EAE model, the 
method of intravital two-photon laser scanning microscopy (TPLSM) has been used to 
visualize the entry process of TMBP cells into the SC. Three levels of T-cell invasion have been 
proposed (Figure 3). The first level consists in the intraluminal crawling of TMBP cells, 
scanning the inner endothelial vessel wall. After diapedesis through the vessel wall into the 
SC leptomeninges, TMBP cells scan the perivascular space (level 2), finally detaching from the 
abluminal vessel wall and migrating through the leptomeninges (level 3). Here, the TMBP cells 
encounter their antigen at local APCs, become re-activated and subsequently penetrate 
deeper into the SC parenchyma (Bartholomäus et al., 2009). This local re-activation in SC 
leptomeninges and parenchyma was visualized in situ by Lodygin and colleagues, using a 
TMBP cell line expressing fluorescently labelled NFAT  (Lodygin et al., 2013). 
. 
 
I.2.2. Grey matter EAE models 
Figure 3: Schematic picture illustrating the invasion steps of TMBP-GFP cells into the CNS tissue. 
(Level I) TMBP cells move intraluminally, scanning the inner endothelial vessel wall. (Level II) After diapedesis 
through the vessel wall, TMBP cells scan the perivascular space, moving on the abluminal vessel wall. (Level III) 
TMBP cells detach from the vessel and migrate through the leptomeninges. Here, the TMBP cells encounter their 
antigen at local APCs, become re-activated and subsequently penetrate deeper into the SC parenchyma. 
Adapted from Bartholomäus et al., 2009 
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Despite the prominent need outlined above, few EAE variants exist to model primary 
grey matter pathology. In marmosets it is possible to induce cortical lesions by inciting 
immune reactivity against PLP or MOG (Pomeroy et al., 2005; Merkler, Boscke, et al., 
2006; ’t Hart et al., 2017). However, the general limitations of primate models (husbandry, 
life-cycle, lack of genetic manipulation) prohibit a widespread use of this approach. In 
rodents, immunization of Dark Agouty rats with CNS homogenate leads to a disease course 
with relapsing remitting and chronic characteristics as well as synaptopathy and cortical 
atrophy (Tambalo et al., 2015). In Lewis rats immunized against MOG, cortical injection of 
tumour necrosis factor alpha (TNFα) and interferon gamma (IFNγ) leads to the formation of 
transient cortical demyelinating lesions (Merkler, Ernsting, et al., 2006). Storch and 
colleagues further described that some Lewis rat strains are susceptible to the development 
of cortical lesions in response to active immunization with MOG (Storch et al., 2006). Also 
astrocytic or neuronal antigens can be used to induce cortical pathology. Indeed targeting 
astrocytes by the passive transfer of S100β-specific T cells elicits inflammation in the entire 
CNS, but only mild clinical symptoms (Kojima et al., 1994). Huizinga and colleagues used 
neurofilament light protein as an antigen to immunize ABH mice. This protein was chosen, 
as antibodies against it are frequently found in the CSF of progressive MS patients (Silber et 
al., 2002). While this approach was successful in the induction of clinical disease and 
produced prominent grey matter lesions as well as axonal damage in the SC, an affliction of 
the cortex could not be demonstrated (Huizinga et al., 2007, 2008). Derfuss and colleagues 
observed that MS patients show autoantibodies and Th1/Th17 cell reactivity against 
contactin-2/transiently expressed axonal glycoprotein 1 (TAG-1), a protein that is expressed 
in a variety of neuronal populations (Derfuss et al., 2009). The resulting rat model shows 
mild clinical symptoms and inflammation is most pronounced in the white matter of brain 
and SC, whereas grey matter inflammation is mainly restricted to perivascular areas. Finally, 
the neuronal EAE model this thesis is concerned with is based on the encephalitogenic 
potential of the neuronal antigen β-Synuclein; it is described in detail in the next chapter. 
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I.2.3. The β-Synuclein neuronal EAE model 
The small, soluble proteins of the Synuclein family (α-, β- & γ-Synuclein) are found 
abundantly in presynaptic terminals throughout the CNS (George, 2002). They were shown 
to regulate the size of the presynapse and play a role in organizing the synaptic vesicle pool 
(Murphy et al., 2000; Vargas et al., 2017). Further, they have been implicated in synaptic 
vesicle exo- and endocytosis, as well as membrane regulation (Middleton & Rhoades, 2010; 
Westphal & Chandra, 2013; Vargas et al., 2014). The most prominent member of the 
Synuclein family is α-Synuclein, notorious for its role in the formation of Lewy bodies in the 
dopaminergic neurons of sporadic and hereditary forms of Parkinson’s disease (Mouradian, 
2002). β-Synuclein, on the other hand, has been shown to counteract the generation of 
these pathogenic aggregates (Wright et al., 2013; Brown et al., 2016). In humans, 
β-Synuclein is most abundantly found in the cortex, thalamus, hippocampus, caudate 
nucleus and in the amygdala (Lavedan et al., 1998; Galvin et al., 2001; Giasson et al., 2001). 
In the rat, where β-Synuclein shares 98% homology with the human protein (Altschul et al., 
1990; SNBC, ID: 6620 & 113893), the expression is most prominent in the cortex, 
hippocampus, olfactory bulb, striatum, thalamus and to a lesser extent in the brain stem 
(Jakes et al., 1994; Iwai et al., 1995; Murphy et al., 2000; Giasson et al., 2001).  
Examining potential targets of autoimmune reactivity in the CNS, Mor and colleagues were 
investigating CNS peptides with an association to neurodegeneration and a predicted fit to 
the Lewis rat MHC class II I-A molecule RT1.B1 (Mor et al., 2003; Mor & Cohen, 2006). In two 
studies they analysed a total of 70 peptides originating from 40 different CNS proteins, such 
as prion protein, Synaptotagmins, Huntingtin, postsynaptic density proteins and the 
Synucleins. Only two of the investigated peptides were found to induce an EAE-like 
phenotype in recipient rats, both subsets of the protein β-Synuclein. The β-Synuclein93-111 
peptide (βSyn) was found to be capable of the induction of active EAE upon immunization 
and the generation of pathogenic βSyn-specific T cell lines (TβSyn cells). In order to induce 
ptEAE, relatively high numbers of TβSyn cells were transferred (2x107 cells) and a pre-
treatment with radiation or cyclophosphamide was shown to exacerbate EAE symptoms. 
One additional work was published on this model, addressing autoimmune spread in 
β-Synuclein induced EAE (Kela-Madar et al., 2009). Here, the encephalitogenic potential of 
the β-Synuclein92-110 peptide in irradiated or cyclophosphamide-treated rats was confirmed. 
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Kela-Madar and colleagues further demonstrated the generation of T and B cells specific for 
other neuron- and myelin-antigens after the primary encephalitogenic attack. While 
inflammatory infiltrates were described in the cerebral cortex in the original publication, 
TβSyn-cell infiltration into the brain or the consequences thereof were never specifically 
addressed in any of these studies. 
Laying the foundations for the work presented here, the neuronal βSyn EAE model was 
examined in our lab by Corinna Schlosser in her dissertation (Schlosser, 2013). Amongst 
other things, she characterized the cells of the TβSyn line as CD4+CD8-, exhibiting a mixed 
Th1/Th17 phenotype and identified their expression profile using quantitative real-time PCR 
(qPCR). Using an ex vivo migration essay, chemokine responses were measured. The cells 
were found to be very similar to TMBP cells, but showed a strikingly different infiltration 
pattern, homing preferentially into the grey matter of brain and SC. Further, the occurrence 
of atypical symptoms in a small fraction of TβSyn-cell recipient animals was described. 
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I.3. Aims 
The aim of this thesis was to characterize active and passive-transfer EAE in the βSyn 
neuronal EAE model. To this end, wild-type and receptor transgenic Lewis rats were 
immunized against βSyn or transferred with βSyn-reactive encephalitogenic T-cell lines. 
Further, I investigated which factors influenced T-cell homing into the target CNS-
compartment by following four approaches: (1) Intravital TPLSM to track motility patterns of 
fluorescently labelled T cells at the CNS vascular bed and inside the target compartment. (2) 
Interference with integrin- and chemokine-signalling. (3) Transcriptome analysis using next 
generation sequencing (NGS). (4) Adeno-associated virus-mediated local increase in βSyn-
antigen availability. Finally, to elucidate the consequences of inflammation on the brain, 
longitudinal MRI was performed in passive-transfer and active EAE and the density of 
synaptic spines on neurons of cortical layers 2 & 3 was examined. 
  
Material  12 
II. Material 
II.1. Proteins 
β-Synuclein39-111 peptide (amino acid 
sequence: LKPEEVAQEAAEEPLIEPL) 
Peptide synthesis service, Biochemical 
Institute, Charité Berlin 
Albumin from chicken egg white (OVA) Sigma Aldrich 
Myelin basic protein (MBP) from guinea pig In-house production 
 
II.2. Antibodies 
CD11a (integrin αL, anti-LFA-1, clone WT.1) Serotec 
CD11b-Setau647 (Hybridoma clone OX-42) In-house production 
CXCR3 (clone XR3.2) Courtesy of Thomas Issekutz 
VLA-4 (anti-CD49d, clone TA-2) Courtesy of Thomas Issekutz 
 
II.3. Media and buffers 
ACK buffer 0.15 mol/L NH4Cl (Roth) 
1 mmol/L KHCO3 (Roth) 
0.1 mmol/L Na2×EDTA (Roth) 
adjusted to pH 7.2 - 7.4 with HCl (Roth) 
Eagles HEPES (EH) medium 188.3 g/10L DMEM powder (Invitrogen) 
HEPES 1M (Roth) 
Freezing medium 80 % heat-inactivated horse serum 
(Biochrom AG)  
10 % TCM (in-house production)  
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10 % DMSO (Roth) 
Isotonic Percoll 9x Vol. Percoll (GE Healthcare) 
1x Vol. 10x PBS (in-house production) 
Lymphocyte separation medium LSM 1077 PAA 
Percoll Underlay 7 mL Isotonic Percoll 
3.9 mL 1x PBS (in-house production) 
Phosphor buffered salt solution (PBS, 10x) 8.10 mM Na2HPO4 (Roth) 
1.47 mM NaH2PO4 (Roth) 
137 mM NaCl (Roth) 
2.68 mM KCl (Roth) 
adjusted to pH 7.2 
Restimulation Medium TCM (in-house production) 
1 % rat serum (in-house production) 
T cell growth medium (TCGM) TCM (in-house production) 
10 % heat-inactivated horse serum 
(Biochrom AG) 
10 % conditioned medium from splenocytes 
treated with the mitogen Concanavalin A 
(ConA supernatant; in-house production) 
T cell medium (TCM) DMEM (Invitrogen) 
10 ml non-essential amino acids (Invitrogen) 
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10 ml penicillin / streptomycin (Invitrogen) 
10 mL sodium pyruvate (Invitrogen) 
10 mL L-glutamine (PAN Biotech GmbH) 
10 mL L-asparagine monohydrate (Sigma 
Aldrich) 
4 µL 2-β-mercaptoethanol (13.6 mol/L) 
(Invitrogen) 
 
Thawing medium 90 % EH medium (in-house production) 
10 % heat-inactivated foetal calf serum 
(Biochrom AG) 
 
II.4. Chemicals, reagents, sera, etc. 
Agarose, Low Melt Roth 
Beads (BD CaliBRITE™) BD Bioscience 
β-mercaptoethanol Roth 
Dextran Tetramethylrhodamine (2 Mio MW) Invitrogen 
Dextran Texas Red® (3000 MW) Invitrogen 
Diethylether Roth 
Dimethyl sulfoxide (DMSO) Roth 
DMEM powder Invitrogen 
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Foetal Calf Serum (FCS) Biochrom AG 
G418-Sulphate (neomycin) Invitrogen 
Gadovist, 1 mM (Gad) Bayer 
HEPES Invitrogen 
Horse serum Biochrom AG 
Hydrochloric acid (HCl) Roth 
Incomplete Freund’s Adjuvant Difco Laboratories 
Isoflurane Abbott 
Isotone sodium chloride solution (NaCl 0.9%) B.Braun 
Ketamine (10%) Medistar Arzneimittelvertrieb GmbH 
M. Tuberculosis H37Ra Difco Laboratories 
Paraformaldehyde (PFA) Roth 
TRI Reagent® Sigma 
Trypsin EDTA (10-fold) PAA 
Xylariem Ecuphar 
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III. Methods 
III.1. Wild-type Animals 
For all experiments Lewis rats on a LEW/Crl background (Rattus norvegicus) were used. The 
animals were bred and kept at the animal facility of the university medical centre Göttingen 
or obtained from Janvier (Le Genest St Isle, France). The animals were kept on a 12 hours 
light-dark cycle. They were provided with food ad libitum. All experiments were performed 
according to local regulations of animal welfare of Lower Saxony. 
 
III.2. Receptor-transgenic rat lines 
T cell receptor (TCR) cloning for the genesis of transgenic rats (βSyn-specific line βSynTG & 
MBP-specific line MBPTG) was performed in house by Dr. Alexandra Kitz and Dr. Dmitry 
Lodygin as described (Kitz, 2013). Briefly, established effector T cell lines were used in the 
reconstruction of βSyn- and MBP-specific TCRs. After single-cell-dilution, clones were 
expanded and tested by restimulation. TCRα and β chains were amplified and sequenced. 
Recombinant TCRα and β chains were tested for successful combination by viral transfer 
into receptor-negative hybridoma. Lentiviruses carrying genes for two TCR chains and GFP 
as a fluorescent marker were then used for transduction of early Lewis rat embryos. This 
transduction was performed as reported (Mullins & Mullins, 1996) by Dr. Henrike Fischer, 
then of the Institute of Cellular and Molecular Immunology, Department of Experimental 
Immunology, University Medical Centre Göttingen. Briefly, a solution containing 
concentrated lentivirus was injected into the perivetelline space of single cell embryos 
isolated from superovulated Lewis females. Injected zygotes were cultured overnight and as 
two-cell stage embryos transferred into the oviduct of pseudo-pregnant recipient Wistar 
females. Genotyping/Identification of founders was performed by FACS and PCR. 
 
III.3. Active EAE & Immunization for the generation of T-cell lines 
6-8 week old female Lewis rat were immunized subcutaneously (into the base of the tail and 
into the hind limb popliteal cavity) with 150 μL guinea pig MBP protein, β-Synuclein93-111 
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peptide or OVA (1 mg/mL) emulsified in an equal volume of complete Freund’s adjuvant 
containing Mycobacterium tuberculosis (2 mg/mL). For MBPTG(T/+) rats, 100 µL guinea pig 
MBP protein (0.4 mg/mL) and CFA (1 mg/mL) were used. The emulsion was prepared with 
the help of tuberculin glass syringes and a custom-made homogenizer. For the generation of 
primary T-cell culture, animals were sacrificed 10 days after immunization, except βSynTG 
rats, which were sacrificed 6 days after immunization. The body weight of the animals was 
determined over the whole experimental period and animals were observed for disease 
symptoms. Clinical signs of classical EAE were measured by daily scoring of the animals 
according to Table 1. Animals were sacrificed when reaching a score of 3.5.  
 
III.4. Assessment of EAE clinical symptoms 
Clinical signs of EAE were assessed according to the score system indicated in Table 1. 
Animals were sacrificed when reaching a score of 3.5. 
Table 1: Clinical symptoms of EAE 
Typical EAE symptoms Atypical EAE Symptoms 
Score Symptoms Score Symptoms 
0 No clinical symptoms 0 No clinical symptoms 
0.5 Reduced tail tone or partial tail 
paralysis 
1* Ataxia, occasional twitches and 
scratching 
1 Tail paralysis 2* Frequent twitches and 
scratching, slight imbalance 
2 Gait disturbance/Ataxia 2.5* Pronounced imbalance 
3 Hind limb paralysis 3* Spastic paresis of hind limbs 
4 Tetraparesis 4* Tetraparesis 
5 Moribund 5* Moribund 
 
III.5. Culture of packaging cells 
GP+E86 packaging cells, producing a replication-deficient eGFP or mCherry retrovirus, were 
used to transduce T cells. The retroviral vector pMSCV used for the gene transfer is derived 
from the murine embryonic stem cell virus (MESV) and promotes the transfer of a resistance 
to neomycin in combination with the eGFP or mCherry sequence. Before co-culturing with 
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primary T cells, packaging cells were cultured in selection medium (T cell medium (TCM) 
containing 10% of foetal calf serum (FCS) and neomycin (2 µg/mL) in 10 mL cell culture 
dishes). The cells were kept under 5% CO2 humidified atmosphere in an incubator at 37°C. 
During cell culture the adhesive packaging cells form monolayers. Upon reaching a 
confluence of 70-80% the packaging cell lines were split. For that purpose the cells were 
washed once with 1xPBS and then incubated for 3-5 min with the endopeptidase trypsin 
(10x stock solution diluted 1:10 with PBS). After detachment of the cells from the cell dish 
the digestion process by trypsin was stopped by adding medium containing 10% FCS. The 
desired amount of cells was taken and centrifuged to remove trypsin residues. After a 
centrifugation for 5 min with 1200rpm at 4°C the supernatant was discarded and the pellet 
was resolved in TCM containing 10% of FCS and 2 μg/mL neomycin. Before co-culturing with 
primary T cells, the packaging cells were cultured for 2 days without any specific selection 
agent until a confluence of 70% was reached. 
 
III.6. Primary rat T cell culture 
T cells retrovirally engineered to express fluorescent proteins and reactive against βSyn, 
MBP or OVA (TβSyn, TMBP or TOVA) were generated as reported (Flügel et al., 1999). The cells 
were kept under 10% CO2 humidified atmosphere at 37°C. For establishing antigen-specific 
CD4+ T cell lines, cells of the draining lymph nodes (popliteal, inguinal and paraaortal LNs) of 
immunized animals were isolated in the preclinical phase of the disease at day 10 after 
immunization. In βSynTG(T/T) rats, the cells were isolated 6 days after immunization. The 
isolated LNs were minced and separated through a metal mesh. The cell suspension then 
was centrifuged (1200rpm, 8 min, 4°C) and the cell pellet was washed once with Eagles 
HEPES (EH) medium. Subsequently, lymphocytes were adjusted to 2x106 per mL and co-
cultured with 1.5x105 per mL packaging cells. The cells were kept in a total volume of 100 µL 
re-stimulation medium (RM) in U-bottom 96-well plates containing their respective antigen 
(7 µg/mL βSyn, 5 µg/mL βSyn for βSynTG(T/T) cells, 10 µg/mL for MBP and OVA). Two days 
after the start of the primary cell culture, T cell growth medium (TCGF) was added (50 μL 
per well). TCGF contains the supernatant of murine splenocytes stimulated with the 
mitogen Concanavalin A (ConA supernatant). ConA supernatant contains the growth factor 
Methods  19 
IL-2 which induces the proliferation of T cells in culture. At day 3 or 4 of primary cell culture 
50 μL of medium per well were removed and cells were transferred into flat bottom 96-well 
plates. After the transfer 100 μL fresh TCGF containing neomycin (1 μg/mL) were added per 
well. Negative selection with neomycin was maintained for 10 days. The first stimulation of 
T cells was performed 7 days after start of the culture (5 days for βSynTG(T/T) cells). Firstly, 
100 μL medium per well were removed and subsequently 1.4x106 irradiated thymocytes in 
100 μL RM were added per well in the presence of the respective antigen (7 µg/mL βSyn, 
5 µg/mL βSyn for βSynTG(T/T) cells, 10 µg/mL for MBP and OVA). The irradiation dose for the 
thymocytes (that were used as APCs) was 30 gray (Gy). Two days after re-stimulation 50 μL 
TCGF were added in each well to propagate T-cell proliferation. Three to four days after re-
stimulation, the T cell wells with the best viral transduction rate (measured by fluorescence 
intensity and the best growth capacity of the cells) were chosen and pooled into 60 mm 
dishes. 
 
III.7. Re-stimulation of T cells 
In the further propagation cycles T cells were re-stimulated in 60 mm dishes in a weekly 
rhythm. For this purpose 3.5x106 resting T cells were co-cultured with 70x106 irradiated 
thymocytes (30 Gy) per dish in RM containing the appropriate concentration of the antigen 
(7 µg/mL βSyn, 5 µg/mL βSyn for βSynTG(T/T) cells, 10 µg/mL for MBP and OVA). At day 2 
after re-stimulation TCGF was added to the T cell culture to promote further proliferation. 
To maintain optimal density T cells were transferred into 10 cm culture dishes and split 
further when necessary. 
 
III.8. Passive transfer EAE 
Passive transfer EAE (ptEAE) was induced by intravenous injection of activated, 
encephalitogenic T-cell blasts (day 2 after stimulation) in 1 mL of EH medium into the tail 
vein of healthy Lewis rats (between 6-8 weeks of age) that were narcotized with 
diethlyether. Unless stated differently, the following amount of cells was injected: TβSyn 
8-9x106 cells, TβSyn(T/+) 6-7x106 cells, TβSyn(T/T) 2-3x106 cells, TOVA 5x106 cells, TMBP 5x106 cells. 
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The body weight of the animals was determined over the whole experimental period and 
animals were observed for disease symptoms. Clinical signs of classical EAE were measured 
by daily scoring of the animals according to Table 1. Animals were sacrificed when reaching 
a score of 3.5. The injection of TOVA cells did not induce EAE. 
 
III.9. Intravital imaging with the two-photon laser scanning microscope 
Two-photon laser scanning microscopy (TPLSM) was used for imaging motility patterns of 
fluorescently labelled T cells within CNS compartments in living animals. In order to access 
the dorsal spinal cord meninges the “open spine window” procedure was performed as 
previously described (Bartholomäus et al., 2009). To access the parietal cortex the “open 
skull window” preparation was performed as previously described (Schlosser, 2013). 
 
III.10. Surgical procedure for intravital two-photon laser scanning microscopy 
Animals were anaesthetized by intra-muscular injection of 10 mg/kg xylazine combined with 
50 mg/kg ketamine. Thereafter, animals were intubated via a small incision of the trachea 
and immediately ventilated with 1.5–2% isoflurane using a custom built ventilation system. 
This system was driven by an Inspira Advanced single animal pressure-controlled ventilator 
(Harvard Apparatus, Holliston, USA). Medical oxygen and pressurized air were routed 
through an isoflurane vaporizer (Uno Roestvaststaal BV, Zevenaar, Netherlands) and several 
gas reservoirs. During imaging, animals were stabilized in a custom-made microscope stage 
and their body temperature regulated and maintained (36-37°C) via a heated pad connected 
to a custom-built thermo-controller. Fluid supply during imaging sessions was warranted by 
using a perfusor (Ismatec SA, Wertheim, Germany) device. For intravital TPLSM recordings 
in the dorsal spinal cord meninges, the “open spine window” procedure was performed as 
previously described (Bartholomäus et al., 2009). Briefly, a midline skin incision of 2-3cm 
was performed followed by subsequent detachment of the paravertebral musculature from 
the spine. Thereafter, a laminectomy on one of the three exposed vertebral bodies was 
performed. To access the parietal cortex the “open skull window” preparation was 
performed as previously described (Schlosser, 2013). Briefly, the connective tissue attached 
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to the skull was carefully removed. Subsequently, a high-speed micro-drill with a 
prophyclean dental drill tip was used to cut an ellipsoid area of the skull between the 
coronal, transverse and sagittal suture and the dura mater carefully removed. For all 
preparations, tissue was immediately covered with sodium-chloride solution (B.BRAUN, 
Melsungen, Germany) after exposure in order to prevent dehydration. 
 
III.11. Two-photon laser scanning microscopy 
Two photon laser scanning microscopy (TPLSM) was performed using a Zeiss Laser Scanning 
Microscope 710 (Carl Zeiss AG, Oberkochen, Germany) combined with a Coherent 10 W 
Ti:Sapphire chameleon laser (Coherent Inc., Santa Clara, USA), running the Zeiss ZEN 2012 
software (Carl Zeiss AG). The excitation wavelength was tuned to 880nm or 1010nm and 
routed through a 20x water NA1.0 immersion objective W Plan Apochromat (Carl Zeiss AG). 
Typically, areas of 424.27 x 424.27 μm (512 x 512 pixel) width were scanned and 50-100 μm 
z-stacks were acquired. The acquisition rate during bidirectional scanning was 
approximately 1.3s per z-plane including 2 times line-averaging. Importantly, for 
reproducible motility analyses, the interval time was kept exactly to 32sec while varying the 
numbers of z-sections (usually between 18 and 27) or distances between 2 z-planes (step-
size, typically between 2 and 5 µm). Emitted fluorescence was detected using non-
descanned detectors equipped with 442/46nm, 550/49nm and 624/40nm band-pass filters. 
Blood vessels were labelled by injection of 2.000.000 MW dextran tetramethylrhodamine. 
Meningeal phagocytes were labelled by intrathecal injection of 3000 MW Dextran Texas Red. 
In general, imaging of the parietal cortex and of the dorsal SC meninges was performed with 
10-15% (880 nm) or 60-70% (1010 nm) of the laser power. For 3D time-lapse movies, 
scanning intervals of 32 sec and 58 cycles were used. After completion of the imaging 
session the animals were sacrificed. The brain and SC tissue were used for further 
histological analysis. To label myeloid cells, a monoclonal antibody against CD11b 
(Hybridoma clone OX-42) labeled with the fluorescence dye SeTau647 was injected 
intravenously 16 hours before TPLSM. 
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III.12. Analysis of time-lapse videos 
Acquired 3D time-lapse videos were analysed with the help of the Imaris 8.0.1 software 
(Bitplane AG, Zurich, Switzerland). In a first step, the automatic cell tracking function was 
used. Afterwards, the automatically generated T cell tracks were evaluated and corrected 
manually. Quantifications were done manually or in a semi-automated fashion using the cell 
tracking feature of Imaris. Subsequently, the percentage of rolling and crawling cells was 
calculated. The track properties of intraluminal and extravasated crawling T cells were 
exported to Microsoft Excel 2010 (Microsoft Corp., Redmond, USA) for further analysis. For 
the analysis of motile extravasated cells, tracks with a lower duration than 10 min and 
stationary cells were excluded. The generation of graphs and statistical evaluation was 
performed using GraphPad Prism 7.03 software (GraphPad Software, Inc., La Jolla, USA). For 
the generation of figures, single z-stacks or overview image files acquired with the TPLSM 
were exported as maximum intensity projections in TIF format by using the Zen 2012 
software. The TIF files were loaded in the Fiji software (Schindelin et al., 2012) and the 
images were corrected in tones and contrast for the different channels using the curve 
function. Moreover, three dimensional z-stacks or overviews of the imaging field were 
exported into the Imaris 8.0.1 software for 3D reconstruction. 
 
III.13. Animal preparation and organ processing  
Rats were sacrificed at time points of interest after adoptive transfer by CO2 inhalation. All 
dissected organs were kept in EH medium on ice. In order to measure the number of 
infiltrated T cells in organs of interest, the different tissues were first weighed and then 
further processed as described below. 
 
III.14. Isolation of PBMCs from blood 
Blood was taken by cardiac puncture in 200 µL 80 mM EDTA containing syringes. Blood 
samples were diluted with equal volume of 1x PBS und layered over 0.5 volume lymphocyte 
separation medium. Samples were centrifuged at 2000 rpm, 22°C for 30 min with minimal 
acceleration ramp and brakes turned off. Peripheral blood mononuclear cells (PBMCs) were 
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taken from the interphase between plasma and separation medium, transferred into new 
Falcon tube and washed with cold 1x PBS. 
 
III.15. Isolation of leukocytes from spleen 
Single cell suspension from spleen was prepared by homogenizing tissue through a metal 
grid in EH medium. After centrifugation at 1200 rpm for 8 minutes at 4°C, the cell pellet was 
resuspended and incubated for 4 minutes in 4 mL ACK-buffer for erythrocyte lysis. 
Subsequently cells were washed in cold 1x PBS and resuspended in 15 mL EH medium. 
 
III.16. Isolation of leukocytes from CNS and CNS meninges 
Brain and spinal cord were dissected and the meninges were removed from the parenchyma. 
Tissues were homogenized in EH medium through a metal grid und suspension were 
centrifuged for 8 minutes at 1200 rpm at 4°C. To remove infiltrated leukocytes from myelin, 
pellets were resuspended in 25 mL EH medium and mixed with 10 mL isotonic Percoll 
solution. Afterwards 10 mL Underlay Percoll was gently pipetted under the cell suspension 
und centrifuged with 2780 rpm for 30 minutes at RT with minimum acceleration ramp and 
no brakes. The interphase of the sample was collected and transferred to a new tube und 
washed with cold 1x PBS. After centrifugation with 1200 rpm for 8 minutes at 4°C 
supernatant was discarded and cell pellet was resuspended in 1 mL EH medium. 
 
III.17. Flow cytometry 
1-5x106 cells per sample were surface stained in 100 µL FACS buffer with combinations of 
monoclonal antibodies labelled with fluorochromes for 30 minutes on ice. After staining, the 
samples were washed and resuspended in 100 µL FACS buffer. Stained cells were analysed 
on a BD FACSCalibur flow cytometer (BD Biosciences, San Jose, USA). Final analysis was 
performed using FlowJo software (BD Biosciences). The transferred T cells could be tracked 
due to their expression of fluorescent reporters. 
Methods  24 
III.18. Cell sorting 
Animals were sacrificed by CO2 inhalation. Organs were dissected and prepared as described. 
Cell sorting was performed by using a BD FACSAria III (BD Biosciences) with minimum flow 
speed at 4°C. The sorted cells were transferred into Eppendorf tubes and centrifuged with 
4000 rpm for 4 minutes at 4°C. Subsequently the cell pellet was resuspended in 250 µL TRI 
Reagent and stored at -80°C. 
 
III.19. Next generation sequencing 
Next generation sequencing (NGS) of sorted TβSyn cells was performed at the Microarray and 
Deep-Sequencing Core Facility of the University Medical Centre Göttingen. The analysis was 
performed by Kaamini Raithatha, Microarray and Deep-Sequencing Core Facility, University 
Medical Centre Göttingen. Further readouts, graphs and statistics in Microsoft Excel 2010 
(Microsoft Corp.) and GraphPad Prism 7.03 (GraphPad Software, Inc.) were performed by Dr. 
Francesca Odoardi and Moritz Hermann. TMBP cell NGS data was used with permission from 
Schläger et al., 2016. 
 
III.20. Analysis of neuronal synaptic spine density 
At EAE peak, animals were trans-cardially perfused with ice-cold 1xPBS (2 min) and 4% PFA 
(8 min). Hemispheres were then separated and post-fixed in 4% PFA for 30 min. One 
hemisphere was set aside for histology; the other embedded in 2-3% low-melt agarose 
(Roth) and cut into 300 µm thick slices on a vibratome. Slices were washed 3x 15 min in 
1xPBS. DiI staining was performed as described (Rauskolb et al., 2010). In brief, DiI-coated 
tungsten particles were delivered to the slices using a hand-held gene gun (Helios Gene Gun 
System, Bio-Rad, Hercules, USA). Images were acquired by confocal microscopy (see below). 
Synaptic spines were counted on the apical dendrites of DiI-stained cortical layer 2/3 
neurons using Fiji (6-8 dendrites per animal). DiI staining, mounting of slices and quality 
control was done by Dr. Marta Zagrebelsky-Holz, Abteilung Zelluläre Neurobiologie, 
Zoologisches Institut der Technischen Universität Braunschweig. Animal preparation was 
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performed by Dr. Francesca Odoardi and Moritz Hermann. Confocal microscopy and 
analyses were performed by Moritz Hermann. 
III.21. Confocal Microscopy 
Confocal microscopy was performed using a Zeiss Laser Scanning Microscope 710 (Carl Zeiss 
AG), running the Zeiss ZEN 2012 (Carl Zeiss AG) software. Fluorophores were excited using a 
488 nm Argon laser for GFP and a 561 nm DPSS laser for mCherry or DiI. For DAPI a 405 nm 
UV-diode was utilized. Accordingly filters were set from 415 to 470 nm for DAPI acquisition, 
498 to 546 nm for GFP and 571 to 660 nm for mCherry/DiI. A 40x oil NA1.3 immersion 
objective Plan Apochromat objective (Carl Zeiss AG) was used. Images were acquired using a 
pinhole size of 50 µm, 8bit scan-depth with 800 x 256 pixels resolution and 2x zoom. A z-
step size of 0.5 μm was chosen to guarantee optimal z-resolution. For overview pictures, 
larger scanning areas and higher z-step sizes were used.  
 
III.22. Adeno-associated virus transfer 
In order to express βSyn and GFP, or GFP alone in rat brain neurons (under the human 
synapsin 1 gene promoter), injections of Adeno-associated virus (AAV) into neonatal rats 
was performed by Dr. Sebastian Kügler, Department of Neurology, Viral Vectors Lab, 
University Medical Centre Göttingen, as described (Kügler et al., 2003). 
 
III.23. Interference with integrin signalling 
To block integrin-mediated binding, a neutralizing mouse anti-rat monoclonal antibody 
against VLA-4 (anti-CD49d, clone TA-2; courtesy of Thomas Issekutz) and/or against CD11a 
(integrin αL, anti-LFA-1, clone WT.1, Serotec) was injected i.v. at a single dose of 1 mg/kg 
during intravital TPLSM recordings or twice, at day 3 and 4 after transfer, for clinical 
experiments.  
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III.24. Interference with chemokine signalling 
Interference with chemokine signalling was achieved by 1 mg/kg hamster anti-rat 
CXCR3mAb (clone XR3.2, courtesy of Thomas Issekutz) injected i.v. during intravital imaging. 
These monoclonal antibodies or blocking agents were shown to be effective in vivo in EAE 
models (e.g. Sporici & Issekutz, 2010). 
 
III.25. Rotarod 
To evaluate motor performance, wheel-running tests were performed on a motorized 
rotarod device (Boenig & Kallenbach oHG, Dortmund, Germany) as described (Kutschenko et 
al., 2016). Rats were trained before EAE induction and tested after full recovery. Speed was 
set successively at 5, 9, 12, 16 and 21 rpm. Each training or test run was followed by 5 
minutes of rest. For each velocity, rats had 4 tries to walk on the wheel-axis until the goal of 
180 seconds was reached. The number of tries needed to reach the goal was recorded. 
Failure to stay on the wheel-axis until the goal was achieved was counted as 4 tries. Training 
and testing were performed by Angelika Mönnich, analyses by Moritz Hermann. 
 
III.26. Statistical Analysis 
Statistical evaluation was performed using the GraphPad Prism 7.03 software (GraphPad 
Software, Inc.). Used tests and confidence intervals are indicated in the figure legends. 
 
III.27. Magnetic resonance imaging (MRI) 
Animals were anaesthetized by intra-muscular injection of 10 mg/kg xylazine combined with 
50 mg/kg ketamine. Thereafter, animals were intubated with a purpose-built endotracheal 
tube and artificially ventilated using an animal respirator (TSE, Bad Homberg, Germany) with 
a respiratory rate of 40 breaths/min and a tidal volume of 0.8 mL. The animals were then 
placed in a prone position on a purpose-built palate holder equipped with an adjustable 
nose cone. Respiratory movement of the abdomen as well as rectal temperature were 
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monitored by a unit supplied by the manufacturer (Bruker Biospin MRI GmbH, Ettlingen, 
Germany). 
At 9.4 T, radiofrequency excitation and signal reception were accomplished with the use of a 
birdcage resonator (inner diameter 7 cm) and a 4-channel phased-array surface coil, 
respectively (all from Bruker Biospin MRI GmbH). T2-weighted axial MRI with repetition time 
(TR) of 9286 ms, echo time (TE) of 11 ms, RARE factor of 12, 60 slices, in-plane resolution of 
120×120 µm, slice thickness of 480 µm, and total acquisition time (TA) of 195 s as well as 
sagittal MRI (TR/TE = 4333/11 ms, RARE factor = 12, 28 slices, in-plane resolution = 120×60 
µm, slice thickness = 480 µm, and TA = 182 s) were performed with the use of multislice fast 
spin-echo MRI. T1-weighted fat-suppressed gradient-echo MRI (3D FLASH, TR/TE = 14.8/4.2 
ms, flip angle = 25°, and TA = 16 min) was performed at an isotropic resolution of 120 µm 
before and after an intravenous injection of a solution of the gadolinium-based contrast 
agent Gadobutrol (30 µL of 1 mM Gadovist dissolved in 0.5 mL physiological saline). The 
analysis followed a strategy previously developed for intra-individual comparisons of MR 
images (Watanabe et al., 2004). 
For the evaluation of MRI signal intensities (SI), regions-of-interest were selected in a 
standardized manner (Figure 4 A-D). Mean signal intensity was measured for all ROIs and 
normalized to the SI of the thalamus. Subsequently, a ratio was calculated by dividing the 
normalized SI after gadolinium injection to the normalized SI before injection. To measure 
the thickness of the cortex and corpus callosum (Figure 4 E), the corpus callosum was 
marked, ca 0.5 mm lateral from the mid-sagittal section, by two parallel lines. The distance 
between those lines was measured at both end points to determine corpus callosum 
thickness. The cortex thickness was measured at three points from the corpus callosum. The 
measurements were taken in both hemispheres and subsequently averaged. Ventricular size 
was assessed by 3D reconstruction of the third and lateral ventricles from T2-weighted 
images (Figure 4 F). All readouts were performed with the Fiji software, for 3D 
reconstruction the 3D Roi Manager plugin was used (Schindelin et al., 2012; Ollion et al., 
2013).  
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MRI measurements were performed by Dr. Takashi Watanabe (Biomedizinische NMR 
Forschungs GmbH, MPI for biophysical Chemistry). Analyses were performed by Moritz 
Hermann. 
 
Figure 4: Magnetic Resonance Imaging (MRI) 
(A-D) Regions of interest set in T1-weighted sagittal images in order to quantify Gadolinium enhancement. 
Positions: (A) Mid-sagittal (B) ~0.5 mm lateral from mid-sagittal (C) ~3 mm lateral from mid-sagittal (D) ~1 mm 
medial from pole. Regions: 1 Meninges, 2 Corpus Callosum, 3 Thalamus, 4 Cerebellum, 5 Choroid Plexus, 6 
Area Postrema, 7 Brainstem, 8 Epiphysis, 9 Superior Colliculus, 10 Inferior Colliculus, 11 Occipital Cortex, 12 
Parietal Cortex, 13 Frontal Cortex, 14 Hippocampus, 14 Temporal Cortex, 15 Eye. (E) Cortex (red lines) and 
corpus callosum thickness (yellow lines) is evaluated in sagittal T2 sections, ~0.5 mm lateral from mid-sagittal. 
(F) Ventricular volume is determined after 3D reconstruction from coronal T2 sections. Image acquired by Dr. 
Takashi Watanabe (Biomedizinische NMR Forschungs GmbH, MPI for biophysical Chemistry). 
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IV. Results 
IV.1. Characterization of neuronal and classic active EAE in 8-10 week old rats 
Different rat lines were examined concerning their susceptibility to EAE development 
following active immunization of 8 to 10 week old animals with either the neuronal antigen 
β-Synuclein93-111 peptide (βSyn) or the myelin antigen myelin basic protein (MBP). As 
expected, wild-type Lewis rats immunized with MBP developed EAE, characterized by an 
ascending paralysis as described in Table 1 (Page 17). Shortly after the onset around day 12 
after immunization, a peak score of 3 (hind limb paralysis) was reached (Figure 5 B). The 
disease lasted for 6 days and thereafter the animals recovered completely. EAE incidence 
was at 100% (Figure 5 K). No measurable symptoms were seen, however, by immunization 
with βSyn (Figure 5A & K). Receptor transgenic rat lines have been developed in our lab 
where T cells are genetically modified to express a βSyn-specific T cell receptor. In 
heterozygous animals of the βSynTG rat line (βSynTG(T/+)), about half (>45%) of the T cells 
express a TCR specific for βSyn. A majority of these rats (about 80%, Figure 5 K) responded 
to βSyn immunization by classic EAE development with an onset around day 13/14, lasting 
for 6 days until complete recovery (Figure 5 C). EAE course and severity in these animals was 
highly similar to classical MBP EAE in wild-type rats. About 60% of rats of the βSynTG(T/+) 
genotype also developed a fully-fledged EAE in response to immunization with MBP (Figure 
5D & K). Surprisingly, homozygous βSynTG(T/T) rats (where >85% of T cells express the βSyn-
specific receptor) did not develop EAE when immunized with βSyn and only scarcely (12.5%) 
when immunized with MBP (Figure 5E, F & K). Following these observations, heterozygous 
βSynTG(T/+) rats were chosen for all active EAE (aEAE) experiments in this thesis.  
Similar to βSynTG rats, MBPTG rats, previously established in our lab, harbour T cells specific 
for MBP. After substantial MBP/CFA dose reduction in comparison to wild-type, all 
MBPTG(T/+) rats developed a fulminant EAE (Figure 5H & K). First clinical symptoms were 
detected at day 6 and the classical disease course reached its peak around day 9/10. At day 
16 no more signs of EAE could be detected. Unsurprisingly, as in wild-type rats, no reaction 
was evoked by immunizing with βSyn (Figure 5G & K). Rats of the homozygous MBPTG(T/T) 
line showed no response to βSyn either, but react strongly to MBP immunization (Figure 5I, 
J & K). Dose-adjustment was only performed for MBPTG(T/+) rats, since they are the 
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appropriate counterpart for βSynTG(T/+) rats and as such will be used for aEAE induced by 
MBP immunization in later experiments. 
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IV.2. Active neuronal EAE can be induced reliably in up to 6 month-old 
βSynTG(T/+) animals 
To test whether active neuronal EAE could be induced reliably in βSynTG(T/+) rats older than 
10 weeks, cohorts of 14, 18, 25, 30 and 36 weeks were subjected to βSyn immunization. 
Indeed, in animals up to an age of half a year (or more precisely 25 weeks), aEAE could be 
induced reliably in a majority (75% or more) of animals (Figure 6 A-C & F). In these groups, 
EAE development and severity was comparable to younger animals of the same genotype 
(see Figure 5 C): onset was around day 13/14 and the symptoms lasted about 6 days until 
remission. Above this age, incidence rates declined (66.6% in rats aged 30 weeks at 
induction and 60% in rats aged 36 weeks; Figure 6 D-F). Furthermore, the day of onset was 
less reliable in those groups. While some rats still displayed the first clinical symptoms at 
day 13, others remained symptom free until day 17 or 18 post immunization. 
Figure 5: Active EAE in different Lewis rat lines aged 8-10 weeks. 
(A+B) Wild-type Lewis rats develop aEAE when immunized with MBP, but not βSyn. (C+D) βSynTG(T/+) rats 
are susceptible to both, βSyn- & MBP-induced aEAE and show classical disease progression with onset 
around day 14. (E+F) βSynTG(T/T) rats are not susceptible to βSyn-induced aEAE, while a small percentage 
develop aEAE upon MBP immunization. (G+H) MBPTG(T/+) rats do not respond to βSyn immunization, but 
develop fulminant aEAE upon immunization with a reduced MBP/CFA dosage. (I+J) MBPTG(T/T) rats do not 
respond to βSyn immunization, but develop severe aEAE in upon MBP immunization. (K) aEAE incidences. 
(A-J) Data presented as mean±SEM, bars show clinical score, lines indicate weight change. Sample size 
indicated in graphs. Scores: 0 = No clinical symptoms; 0.5 = Reduced tail tone or partial tail paralysis; 
1 = Tail paralysis; 2 = Gait disturbance/Ataxia; 3 = Hind limb paralysis; 4 = Tetraparesis; 5 = Moribund. 
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Figure 6: Active neuronal EAE can be induced in up to 9 months old βSynTG(T/+) rats. 
βSynTG(T/+) rats of 14 weeks and older were subjected to immunization with the neuronal antigen βSyn. 
(A-C) Rats of 14, 18 and 25 weeks of age showed the same disease course as their younger littermates (see 
Figure 5 C): ascending paralysis starting at 13/14 days after immunization, recovering completely after 6 
days of disease. (D&E) Rats aged 30 and 36 weeks still developed EAE, but the day of onset varied between 
day 13 to 18. (F) EAE incidence was 75% at 14 weeks of age, 100% at 18 weeks, 89% at 25 weeks and thus 
at comparable levels to younger littermates (see Figure 5 C). Hereafter, we observed a notable drop in 
incidence to 66.6% at 30 weeks and 60% at 36 weeks of age. (A-E) Data presented as mean±SEM, bars 
show clinical score, lines indicate weight change. Sample size indicated in graphs. Scores: 0 = No clinical 
symptoms; 0.5 = Reduced tail tone or partial tail paralysis; 1 = Tail paralysis; 2 = Gait disturbance/Ataxia; 
3 = Hind limb paralysis; 4 = Tetraparesis; 5 = Moribund. 
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IV.3. EAE induced by transfer of β-Synuclein-specific T cells of different genetic 
origins 
The use of passive transfer EAE (ptEAE) offers the possibility to trace fluorescently labelled T 
cells through the recipient organism, as well as an earlier onset compared to active EAE. 
Transfer of (8-9x106) in vitro activated βSyn-specific T cells (TβSyn cells), generated from wild-
type Lewis rats, led to an EAE course comparable to the classic TMBP induced ptEAE (Figure 
7A & E). At day 4 after transfer, weight loss and the occurrence of the first symptoms of 
ascending paralysis marked the beginning of clinical EAE. Disease peak was reached on day 6 
post transfer (mean score 2.4), after which symptoms abated until at day 10 all outward 
signs of disease had disappeared (Figure 7 A). Of note, a small fraction (<3%) of TβSyn ptEAE 
rats presented with atypical clinical symptoms such as isolated front limp paresis (Schlosser, 
2013). T cells of receptor-transgenic origin could also be used to establish fluorescently 
labelled cell lines. EAE course and severity after transfer of (6-7x106) TβSynTG(T/+) cells was 
similar to wild-type ptEAE: symptoms manifested on day 4 post transfer and reached their 
peak on day 6 (mean score 2.5; Figure 7 B). Weight loss was more pronounced (peak at day 
8 with an average weight loss of 14.98% versus day 7 with 7.86% in TβSyn recipients), but the 
most notable difference was the manifestation of atypical symptoms in 10-20% of TβSynTG(T/+) 
cell recipient rats. Even more striking was the observation that the transfer of homozygous 
TβSynTG(T/T) cells caused an atypical EAE course in virtually all recipient animals. This atypical 
course (denominated by an asterisk behind the score) was dominated by abnormal 
scratching and twitching behaviour as well as progressing imbalance sometimes followed by 
spastic paresis (Figure 7 C). The exact properties and triggers of these unique EAE symptoms 
of course warrant further investigation, will however not be addressed in detail in this thesis. 
EAE peak in TβSynTG(T/T) recipient animals was reached on day 5 post transfer with a mean 
atypical score of 2.4*, weight loss was most pronounced on day 6 with 17.19%. This was 
achieved with the transfer of a mere 2-3x106 T cells and the transfer of higher numbers 
inevitably induced an EAE course with of unsustainable severity (Figure 7 D, mean atypical 
score on day 4 post transfer 3.9*). Unless explicitly stated, all ptEAE experiments in this 
thesis were conducted with fluorescently labelled T cells of wild-type origin. 
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Figure 7: Passive transfer EAE induced by βSyn-specific T cell lines of different genetic origins. 
Transfer of βSyn-specific T cells activated in vitro induces EAE in wild-type Lewis rats. (A) βSyn-specific 
T cells established from wild-type Lewis rats reliably induced an EAE course with classical ascending 
paralysis. (B) Cells of βSynTG(T/+) origin induced EAE as seen in (A). (C) Transferred cells from a 
βSynTG(T/T) background induced a pronounced EAE course, almost exclusively manifesting through 
atypical symptoms. (D) Transfer of 3-5x106 T cells of βSynTG(T/T) origin induced a fatally potent EAE 
course. (E) MBP specific T cells from wild-type Lewis rat induced a classical EAE course. (F) ptEAE 
incidences. Data presented as mean±SEM, bars show clinical score, lines indicate weight change. Sample 
size indicated in graphs. (A-C) Representative graphs of 3 or more independent experiments are shown. 
(A+B) Scores: 0 = No clinical symptoms; 0.5 = Reduced tail tone or partial tail paralysis; 1 = Tail paralysis; 
2 = Gait disturbance/Ataxia; 3 = Hind limb paralysis; 4 = Tetraparesis; 5 = Moribund. (C+D) Atypical Scores: 
1* = Ataxia, occasional twitches and scratching; 2* = Frequent twitches and scratching, slight imbalance; 
2.5* = Pronounced imbalance; 3* = Spastic paresis of hind limbs; 4* = Tetraparesis; 5* = Moribund. 
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IV.4. T-cell infiltration into the rat brain 
As described before, TβSyn cells were found to show a clear preference to infiltrate cortical 
grey matter (Schlosser, 2013). The brain cortex seemed to be one of the primary targets of 
infiltration, where a gradient could be seen starting from the meninges and declining 
towards the corpus callosum, where only very few cells were visible (Figure 8). Although 
grey matter areas, only few cells were found in the hippocampus and thalamus, advocating 
the hypothesis of the meninges as an entry route for encephalitogenic T cells (Schläger et al., 
2016). Many cells could also be found around the ventricles, e.g. the third ventricle just 
above the thalamus. As expected, TMBP cells were only sporadically found in the brain 
parenchyma and localize mainly in the subpial cortex and thalamus, while they are rarely 
detectable in hippocampus or corpus callosum (Figure 9). Again, a number of GFP+ TMBP cells 
were visible around the lateral ventricles.  
 
Figure 8: TβSyn-GFP cells infiltrate the rat brain, where they are found mainly in the cortex. 
Confocal image of TβSyn-GFP cells (green) and DiI+ neurons (white), showing massive infiltration in the 
cortex, while low numbers could be detected in hippocampus, corpus callosum (CC) and thalamus (red 
arrows); above the thalamus, a part of the lateral ventricle containing GFP+ cells can be seen; 
representative section (300µm thick), taken from wild-type Lewis rat transferred with TβSyn-GFP cells, at 
peak of disease (d6 p.t., clinical score 3); scale bars = 200µm. 
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IV.5. TPLSM of T cells at the CNS vascular bed 
The histological findings were mirrored by observations in intravital two-photon laser 
scanning microscopy (TPLSM). Shortly before EAE onset, fluorescently labelled T cells were 
quantified on the surface of brain and SC, i.e. the subpial compartment of the brain and the 
leptomeninges of the SC. The number of cells found to be located inside the CNS vasculature 
was comparable between TβSyn and TMBP cells (Figure 10 A; brain: 10.43±2.57SEM vs 
9.50±2.09SEM; SC: 10.07±2.60SEM vs 4.18±0.69SEM; note that the number of intravascular 
TMBP cells was likely under-estimated caused by an overwhelming amount of perivascular 
cells). But while TMBP cells extravasated preferentially into the SC leptomeninges 
(218.45±48.56SEM) compared to brain subpial parenchyma (11.92±1.91SEM), TβSyn cells 
 
Figure 9: TMBP-GFP cells are found in low number in the subpial cortex and thalamus. 
Confocal image of TMBP-GFP cells (green) and DiI+ neurons (white); infiltration of the brain was generally 
low, few cells could be detected in the subpial cortex and thalamus (red arrows); above the thalamus, a 
part of the lateral ventricle containing GFP+ cells can be seen; representative section (300µm), taken from 
wild-type Lewis rat transferred with TMBP-GFP cells, at peak of disease (d5 p.t., clinical score 3); scale 
bars = 200µm. 
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showed elevated extravasation in both compartments (brain 62.07±20.39SEM; SC 
161.20±25.31SEM). CNS ignorant T cells of OVA specificity were detectable in the vessels as 
well as on the surface of brain or SC in low numbers (brain: i.v. 1.79±0.50SEM, e.v. 
3.21±0.65SEM; SC: i.v. 6.29±0.75SEM, e.v. 7.14±1.27SEM). 
To elucidate whether T-cell locomotion within CNS vessels correlated with their 
extravasation profiles, intravascular motility behaviour was analysed via intravital TPLSM. 
One indicator for the status of the activation of the CNS milieu is the percentage to which T 
cells crawl (as opposed to roll) inside blood vessels (Bartholomäus et al., 2009). Indeed, TMBP 
cells crawled preferentially in the SC (57.37%±3.71SEM) compared to the brain 
(35.80%±4.71SEM). TOVA cells on the other hand showed a low crawling percentage in SC 
(40.51%±4.08SEM) that was even lower in the brain vessels (24.15%±4.47SEM) (Figure 10 B). 
TβSyn cells showed an elevated percentage of crawling cells that was almost identical 
between both compartments (brain 58.32%±5.04SEM, SC 59.50%±5.70SEM). 
Further indication about the activation state of the CNS milieu can be drawn from motility 
parameters, e.g. T-cell velocity and the crawling duration (i.e. the time a single cell can be 
followed via TPLSM) (Bartholomäus et al., 2009). Generally, T cells moving in an inflamed 
milieu display a lower speed and a longer crawling time when comparing their movement in 
an un-inflamed milieu. As shown in Figure 10 C, the velocity did not differ between TβSyn and 
TMBP cells, independent of the compartment. TβSyn cells showed an average velocity of 
13.01µm/min±0.39SEM in the brain vasculature and 11.76µm/min±1.25SEM in the SC.  TMBP 
cells moved with 11.01µm/min±0.77SEM through brain and with 11.42µm/min±1.01SEM 
through SC vessels. TOVA cells were slightly faster with 14.66µm/min±1.41SEM in brain and 
13.76µm/min ±1.02SEM in SC, respectively. The parameter of track duration was little more 
illustrative in regard to the final T-cell distribution (Figure 10 D). The average track duration 
of TβSyn cells was 8.68min±0.90SEM in brain vessels and 10.88min±1.95SEM in the SC, while 
TMBP cells could be observed for 7.70min±0.24SEM in the brain and for 12.71min±1.40SEM 
in SC vasculature. The latter was indeed significantly different between compartments 
(p=0.0079), but not in comparison to the other groups. This most likely reflected upon a 
higher inflammation of the SC parenchyma of TMBP recipient animals, as no significant 
differences could be detected between TβSyn and TMBP cells irrespectively of the examined 
compartment.  Expectedly, TOVA cells crawling at the CNS vascular bed could be observed for 
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an only marginally shorter time with 5.87min±0.77SEM in the brain and 8.38min±0.89SEM 
in the SC. Here a significant difference could be detected for the crawling duration in the 
brain of TβSyn and TOVA recipient animals (p=0.0317), fitting the observation that TOVA cells 
were rarely detected extravasated within the brain tissues. Taken together with the other 
data, the locomotion characteristics of the different effector T cells seems rather to be 
consequential of the general distribution of cells and the subsequent inflammation of the 
surrounding tissues than causative for the disparate distributions of neuron- or myelin-
specific T cells throughout the CNS observed in histology and TPLSM. 
 
Figure 10: in vivo TPLSM in brain and SC of rats transferred with T cells of different antigen specificities. 
Fluorescently labelled βSyn-, MBP or OVA-reactive T cells (TβSyn, TMBP or TOVA respectively) were observed 
shortly before EAE onset in brain and SC. (A) Quantification of T cells per frame, taken from the first frame 
of every 30’ video. (B) Percentage of rolling versus crawling cells inside CNS vessels. (C) Velocity and (D) 
track duration of cells observed over a 30’ period; number of analysed cells indicated in graph. (E) TPLSM 
tile scans from brain and SC of different T-cell recipient animals. Green: T cells. Red: blood vessels and 
(upper two rows) macrophages. Scale bars = 100µm. All data originate from n=5 animals per group in 
independent experiments. In C+D each point is representative of one animal where 4 videos were 
analysed per compartment. Statistical significance determined via Mann-Whitney test. All data presented 
as mean±SEM. 
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IV.6. Monitoring CD11b+ Monocytes at the CNS vascular bed reveals subtle 
differences in luminal crawling between brain and SC 
Looking at the TOVA cell motility data it seemed probable that some fundamental difference 
exists between the vasculature on the surfaces of brain and spinal cord, independent of 
inflammation state, which could influence intraluminal motility behaviour. To test this 
hypothesis, naïve rats were injected with fluorescently labelled CD11b antibody in order to 
mark circulating monocytes. While the overall amount of monocytes detected in brain or SC 
vessels did not differ (18.75±4.24SEM in brain and 20.00±3.16SEM in SC, Figure 11 A), the 
percentage to which these cells crawled was significantly lower in the brain 
(54.53%±5.93SEM) compared to the SC vessels (69.36%2.50SEM, p=0.0369, Figure 11 B). 
Velocity and average track duration on the other hand did not differ significantly from one 
another (Figure 11C & D): the average velocity of CD11b+ monocytes was 
9.72µm/min±1.31SEM in the brain and 11.09µm/min±0.77SEM in the SC (p=0.4192). The 
average track duration with which these cells moved through brain vessels was also not 
altered compared to the SC (9.38min±1.13SEM in brain vs 10.16±1.90 in SC, p=0.7407). It 
can thus be concluded that, while these cells can be observed in similar amounts in brain or 
SC and while their crawling parameters do not significantly differ, there nonetheless may 
exist some inherent minor difference between the CNS vascular compartments which 
influences the T cell adhesion properties to the vascular endothelium observable via TPLSM. 
These subtle differences however are very unlikely to justify profoundly distinct distribution 
 
Figure 11: CD11b+ Monocytes at the vascular bed of naïve rats. 
Fluorescently labelled CD11b+ monocytes were observed in brain and SC of naïve rats. (A) Quantification of 
T cells per frame, taken from the first frame of every 30’ video. (B) Percentage of rolling versus crawling 
cells inside CNS vessels. (C) Velocity and (D) track duration of cells observed over a 30’ period; number of 
analysed cells indicated in graph. (E) All data originate from the same n=3 animals in independent 
experiments. In C+D each point is representative of one animal where 4 videos were analysed per 
compartment. Statistical significance determined via Student’s t-test (A+B) or Mann-Whitney test (C+D), 
*p≤0.05. All data presented as mean±SEM. 
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of TβSyn and TMBP cells in the CNS compartments. 
 
IV.7. Blocking integrin & chemokine receptor signalling affects T-cell crawling 
and EAE development 
Transmigration of TMBP cells from vessels into the SC parenchyma has been shown to be 
dependent mainly on the alpha4/beta1 integrin VLA-4 and not on LFA-1 (alphaL/beta2; 
Bartholomäus et al., 2009; Schläger et al., 2016). Quantitative real-time PCR data revealed 
that TβSyn cells isolated from the blood express high levels of both VLA-4 and LFA-1, 
suggesting that TβSyn cell adhesion to the brain endothelium could be mediated by these 
molecular cues (Schlosser, 2013). To test this hypothesis, TPLSM was performed on the 
brains of rats transferred with TβSyn cells shortly before EAE onset, when TβSyn cells were 
mainly located in the intravascular compartment. Compared to the studies on TMBP cells in 
the SC, the effect of αVLA-4-mAb injection was even more pronounced on TβSyn cells in brain 
vessels. Here, a single injection was sufficient to completely remove any detectable T cells 
within 30-40 minutes (Figure 12A & F). As could be expected, FACS staining of T cells 
extracted from blood after this experiment showed complete blocking of the VLA-4 receptor 
(Figure 12 E). Preventive antibody-treatment consequently inhibited ptEAE development 
(Figure 12 B): over the duration of the experiment no overt clinical signs were detectable in 
treated animals. Stagnation in weight gain was observed however during day 3 to 7 post 
transfer (p.t.) and subsequent FACS analysis revealed low amounts of infiltrating T cells in all 
CNS tissues on day 5 p.t. (Figure 12 C). The ratio of infiltration into the CNS was between 5 
(brain) and 25 times (meninges SC) lower in treated animals compared to control (Figure 12 
D), but the perseverance of cells explains the observed weight stagnation. 
Upon the injection of αLFA-1 blocking antibody, a reduction in the number of observable T 
cells inside brain vessels by about 50% could be detected (Figure 13A & I). It is possible that 
this effect was slightly stronger in rolling and weakly adhering cells, indicated by the slightly 
increased percentage of crawling cells from 36.06%±3.96SEM to 51.01%±12.47SEM within 
one hour after injection (Figure 13 B), this was however not significant (p=0.5611). 
Furthermore, the LFA-1 antibody treatment did not seem to influence the motility 
characteristics of crawling cells, as neither track duration, nor velocity of the observed T 
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cells changed within the observed time frame (Figure 13C & D). Again, blocking of the 
receptor was complete, as indicated by FACS staining (Figure 13 F). According to these 
observations, it was little surprising that preventive treatment of TβSyn-cell recipient animals 
with αLFA-1 blocking antibody had no influence on the clinical outcome compared to PBS 
treated controls (Figure 13 E). Accordingly, FACS analysis revealed no differences in the 
infiltration rate of TβSyn-GFP cells into the CNS compartments (Figure 13G & H): in brain, SC, SC 
meninges and blood, the ratio was around 1, indicating the same infiltration frequency. 
Interestingly, in one of three treated animals, an increased number of TβSyn cells in the brain 
meninges and spleen were detectable, elevating the infiltration ratio to 2.75 and 4, 
respectively.   
Chemokines are supposed to play an important role in T-cell adhesion and transmigration. 
Blocking of the chemokine receptor CXCR3 has been shown to inhibit TMBP-cell induced 
ptEAE development (Sporici & Issekutz, 2010). In murine Th1/17 cells it is important for BBB 
transmigration and it is part of the molecular cluster which can be used to identify 
pathogenic Th1/17 cells in MS patients (Lee et al., 2012; Hu et al., 2017). Previous work has 
also identified a high expression of CXCR3 in TβSyn cells (Schlosser, 2013). However, for the 
intravascular crawling of these cells inside brain vessels it seemed of minor relevance. 
Injection of CXCR3-blocking antibody had no immediate effect on intraluminal TβSyn cells: 
within one hour after injection, no reduction in the number of crawling and rolling TβSyn cells 
within brain vessels could be detected (Figure 14A & E). The values for crawling percentage 
as well as track duration remained stable during the entire observation period as well 
(Figure 14B & C). Only T-cell velocity changed significantly in the 60-90 minute time frame 
(Figure 14 D), increasing from a mean of 11.43µm/min±0.23SEM to 12.58µm/min±0.29SEM. 
This hints to the possibility of a slowly acting mechanism that was not observable during the 
limited time frame of this experiment. Further, it cannot be excluded that the used antibody 
dosage was too low (it was chosen in relation to the experiments with VLA-4 and LFA-1), 
resulting in incomplete blockage, as in our hands no FACS staining could be established for 
the rat CXCR3.  
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Figure 12: VLA-4 blocking washes TβSyn cells from brain vasculature and impedes ptEAE development. 
(A) Intravital TPLSM of rats transferred with TβSyn-GFP cells, day 3 after transfer. αVLA-4 mAb injected at 
30 minutes time point. Cell numbers counted in 5-minute intervals. Black line shows crawling, grey line 
rolling cell percentage relative to 0 minutes time point. n=3, independent experiments (B) Clinical score 
(bars) and relative weight change (lines) of TβSyn recipient rats treated with αVLA-4 mAb on day 3 & 4 p.t. 
(black bars/red line) or PBS-treated controls (white bars/grey line). Sample size indicated in graph. Scores: 
0 = No clinical symptoms; 0.5 = Reduced tail tone or partial tail paralysis; 1 = Tail paralysis; 2 = Gait 
disturbance/Ataxia; 3 = Hind limb paralysis; 4 = Tetraparesis; 5 = Moribund. (C) FACS count of TβSyn-GFP cells 
per gram or mL of tissue extracted, day 5 p.t. White bars show PBS control, black bars αVLA-4-treated 
group respectively. (D) Ratio of extracted cells in treated vs untreated group. (E) FACS staining of VLA-4 
receptor in αVLA-4-treated and PBS-treated controls. (F) Time-lapse images of TβSyn-GFP cells (green) and 
blood vessels (texas red labelled dextran, red) 30 minutes before (left) and after αVLA-4 Ab injection 
(right); Scale bar = 100µm. Antigen concentration for all experiments: 1mg/kg. Data presented as 
mean±SEM. 
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Figure 13: Blocking LFA-1 reduces TβSyn cell adhesion but does not influence crawling or ptEAE 
development. 
(A) Intravital TPLSM of rats transferred with TβSyn-GFP cells, day 3 after transfer. αLFA-1 mAb injected at 
30 minutes time point. Cell numbers counted in 5-minute intervals. Black line shows crawling, grey line 
rolling cell percentage relative to 0 minutes time point. (B) Percentage of rolling versus crawling cells inside 
brain vessels. (C) Track duration and (D) Velocity and of cells observed over 30 minute periods. (A-D) n=3, 
independent experiments. Antigen concentration for all experiments: 1mg/kg. Data presented as 
mean±SEM; Significance determined by Kruskal-Wallis one-way ANOVA with Dunn’s Multiple Comparisons 
Test. ns = not significant. (E) Clinical score (bars) and relative weight change (lines) of TβSyn recipient rats 
treated with LFA-1 mAb on day 3 & 4 p.t. (black bars/red line) or PBS-treated controls (white bars/grey 
line); n=4; Scores: 0 = No clinical symptoms; 0.5 = Reduced tail tone or partial tail paralysis; 1 = Tail 
paralysis; 2 = Gait disturbance/Ataxia; 3 = Hind limb paralysis; 4 = Tetraparesis; 5 = Moribund. (F) FACS 
staining of LFA-1 receptor in αLFA-1-treated and PBS-treated controls. (G) FACS count of TβSyn-GFP cells 
per gram or mL of tissue extracted, day 5 p.t. White bars show PBS control, black bars αLFA-1-treated 
group respectively; n=3; Significance determined by two-way ANOVA with Bonferroni’s Multiple 
Comparisons Test; no significant differences. (H) Ratio of extracted cells in treated vs untreated group. (I) 
Time-lapse images of TβSyn-GFP cells (green) and blood vessels (texas red labelled dextran, red) 30 minutes 
before (left) and after (right) αLFA-1 Ab injection; Scale bar = 100µm.  
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Figure 14: Effect of αCXCR3 mAb injection on TβSyn cell motility. 
(A) Intravital TPLSM of rats transferred with TβSyn-GFP cells, day 3 after transfer. αCXCR3 mAb injected 
at 30 minutes time point. Cell numbers counted in 5-minute intervals. Black line shows crawling, grey line 
rolling cell percentage relative to 0 minutes time point. (B) Percentage of rolling versus crawling cells 
inside brain vessels. (C) Track duration and (D) Velocity and of cells observed over 30 minute periods. 
(E) Time-lapse images of TβSyn-GFP cells (green) and blood vessels (texas red labelled dextran, red) 30 
minutes before (left) and after (right) αCXCR3 Ab injection; Scale bar = 100µm. (A-D) n=3, independent 
experiments. All data originate from the same n=3 animals in independent experiments. Antigen 
concentration for all experiments: 1mg/kg. Data presented as mean±SEM. Significance determined by 
Kruskal-Wallis one-way ANOVA with Dunn’s Multiple Comparisons Test. ns = not significant, *p≤0.05. 
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IV.8. Expression profiles of blood-derived T cells are nearly identical between 
different antigen-specificities 
The similarity between T cells of different specificities in the intravascular phase was 
underlined by their expression profiles discerned via next generation sequencing (NGS; 
Figure 15). TβSyn cells were sorted from blood 3 days after transfer and their transcription 
profile was compared to sequencing data of TMBP cells previously obtained under the same 
conditions (Schläger et al., 2016). Comparing the expression of the most relevant genes for 
cytokine and chemokine receptors, cell adhesion, cell motility and transcription factors (a 
total of 145 genes), only one was found to be differentially regulated: Interleukin 2 receptor 
 
Figure 15: Next generation sequencing of T cells extracted from blood. 
TβSyn cells were sorted from blood at d3 post transfer and their transcriptome compared to the one from 
TMBP cells isolated under the same conditions. Y-Axes show Reads Per Kilobase per Million mapped reads 
(RPKM). Statistical significance determined via Student’s t-test, *p≤0.05. All data presented as mean±SD. 
TMBP sequencing data and list of relevant genes adapted with kind permission from Schläger et al., 2016. 
Results  46 
chain alpha (IL2ra, also known as CD25) was moderately less expressed in TβSyn compared to 
TMBP cells. Together with the quantitative real-time PCR analysis (Schlosser, 2013), these 
data provide further strong evidence that there exist no major differences between T cells 
of different antigen-specificities before they enter the CNS.  
 
IV.9. Motility behaviour of TβSyn cells in the brain grey matter 
After extravasation from the brain vessels, TβSyn cells rapidly accumulated in the subpial 
cortex, increasing their numbers within a few hours from 62.07±20.39SEM to 
311.2±33.21SEM cells per frame at EAE onset (Figure 16 A). At disease peak, the number of 
extravasated cells seemed to increase further to around 500 cells per frame. During their 
patrolling of the extravascular space, T cells interact with local antigen presenting cells, 
where they can encounter their appropriate antigen and become re-activated. Due to these 
 
Figure 16: Analysis of TβSyn-GFP cell extravascular crawling via TPLSM. 
Intra-vital TPLSM of TβSyn-GFP cells in the rat brain grey matter. (A) Quantification of T cells per frame, 
taken from the first frame of every 30’ video (dataset for Pre adapted from Figure 10) & (B) percentage of 
arrested TβSyn-GFP cells before onset (Pre), at onset and at peak of EAE. (C) Velocity & (D) velocity 
frequency of TβSyn-GFP cells during a 30’ observation period at EAE onset. (E) Meandering index of TβSyn-
GFP cells observed over a 30’ period. (F) Representative graph of superimposed trajectories of TβSyn cells in 
one video (n=30 cells, each line representing one cell); Σ: sum of trajectory vectors divided by the number 
of cells. (G) Representative image of TβSyn-GFP cells (green) and blood vessels/APCs (red) at the first frame 
(left) and as a 30’ time-projection (right); Scale bar = 100µm. Pre n=4; Onset n=3; Peak n=1. All data 
presented as mean±SEM. 
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interactions, T-cell velocity is slowed down and the percentage of arrested cells is increased 
(Bartholomäus et al., 2009; Lodygin et al., 2013). In vivo TPLSM of TβSyn cells in the grey 
matter of the brain revealed a similar pattern with an increase in arrested cell percentage 
from 9.32%±1.06SEM in the pre-clinical phase to 15.27%±1.80SEM at EAE onset (Figure 16 
B), suggesting an increased T-cell-APC-interaction at this time point. Several hours later, at 
EAE peak, more than 80% of cells ceased movement and appeared rounded (not shown), 
indicative of initiated apoptosis and presumably the beginning of disease remission (Gold et 
al., 1997). Following these observations, further analysis of motile TβSyn cells inside brain 
grey matter parenchyma at EAE onset was performed. Trajectory analysis revealed that TβSyn 
cells moved with an average velocity of 9.11µm/min±0.12SEM and, while the majority of 
cells (65%) moved with 8-11µm/min, the maximum velocity reached was 16.86µm/min 
(Figure 16 C & D). No directed motion was detectable (Figure 16 F). Interestingly, in a 30-
minute observation time TβSyn cells scanned the entire target tissue freely and thoroughly, 
despite the presumable density of the grey matter parenchyma (Figure 16 G). The 
meandering index however, might give some indication of the laboriousness of navigating 
grey matter parenchyma compared to the meninges. While a meandering index of 1 would 
describe a perfectly straight line, a value approaching 0 describes a highly skewed 
movement path. TβSyn cells in the grey matter parenchyma showed a meandering index of 
0.33 (Figure 16 E). In literature, a slightly higher meandering index of roughly 0.4 was 
described for TMBP cells navigating the SC meninges (Schläger et al., 2016).  
  
IV.10. Comparison of expression profiles between blood- and brain-derived TβSyn 
cells indicates re-activation in situ 
It has been shown that an essential step for EAE development is the local re-activation of 
TMBP cells in the SC (Lodygin et al., 2013). We therefore investigated if the same process 
occurred for TβSyn cells in the brain. Such a local re-activation of T cells in their target tissue 
should be reflected by their expression profile. Therefore, at EAE onset (day 4), TβSyn cells 
were isolated from blood and brain and their expression profiles analysed via NGS (Figure 
17). Of note, gene expression of blood-resident TβSyn cells did not change between day 3 
(see chapter IV.8) and day 4 post transfer and only 7 genes were found to be differentially 
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regulated between those cells (not shown, max. change was -1.08 log2-fold). Signifying 
pronounced expressional changes, of 927 differentially regulated genes, 707 (~76%) were 
found to be up-regulated in brain-derived TβSyn cells compared to the blood (Figure 17). 
Importantly, the up-regulation of many of the most relevant transcription factors (12 of 34 
genes) and cytokines (7 of 21 genes; see also chapter IV.8) in brain-derived TβSyn cells clearly 
demonstrated an elevated activation state of TβSyn cells in the target tissue. In particular, 
several transcription factors related to T-cell activation were significantly regulated (e.g. 
 
Figure 17: Comparison of the expression profiles of TβSyn cells derived from blood and brain. 
TβSyn cells were sorted from blood and brain at d4 post transfer and analysed for differential gene 
expression. In total, 927 genes were differentially regulated (76% up-/24% downregulated in TβSyn cells 
isolated from brain compared to blood). Y-Axes show Reads Per Kilobase per Million mapped reads 
(RPKM).  Statistical significance determined via Student’s t-test, *p≤0.05. All data presented as mean±SD.  
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tbx21 and the IFNγ-responsive STAT1). Among the cytokines a significant up-regulation of 
IFNγ, Il17A and F, IL-2 and IL-21 was observed.  
IV.11. AAV-mediated antigen-availability influences T-cell recruitment and 
motility 
In order to confirm the role of antigen availability in determining T-cell infiltration 
(Kawakami et al., 2004), we aimed to foster specific antigen presentation in the brain by 
cranially injecting new-born pups with an adeno-associated virus either expressing human 
β-Synuclein and GFP (AAV-βSyn-GFP) or as control the fluorescent reporter GFP (AAV-GFP) 
under a neuronal promoter (Kügler et al., 2003). Of note, the human β-Synuclein shares 98% 
homology with the rat protein and the sequence of the peptide 93-111, which is used to 
establish the TβSyn cell lines, is identical (Altschul et al., 1990; Lavedan et al., 1998). At the 
age of 6-8 weeks, ptEAE was induced by injection of (5x106) TβSyn-mCherry cells. Due to limited 
availability of animals, the clinical course was only followed until day 5 post transfer, where 
no significant change between the two groups could be observed, but a trend can be 
surmised (Figure 18 A). It is also possible that a locally restricted overexpression did not 
suffice to evoke disease aggravation. Intravital TPLSM of the parietal cortex revealed 
TβSyn-mCherry cells in close proximity to fluorescently marked neurons at EAE onset (day 4 post 
transfer, Figure 18B & C). Comparative analysis revealed that, while EAE symptoms were 
comparable, three-fold more TβSyn-mCherry cells invaded the cortex of AAV-βSyn-GFP animals 
relative to the AAV-GFP group (560.2±77.31SEM vs 181.2±31.86SEM, p=0.0043, Figure 18 D). 
In line with this finding, the histological analyses revealed increased infiltration of T cells 
into AAV-βSyn-GFP brains, compared to AAV-GFP controls. Local expression of AAV-βSyn-
GFP even seemed to lead to heightened recruitment to areas that were otherwise only 
sparsely infiltrated, like the hippocampus (Figure 18G & H). Analysis of in situ motility data 
showed that TβSyn-mCherry cells in AAV-βSyn-GFP animals moved with notably reduced velocity 
compared to their counterparts in AAV-GFP brains (9.40µm/min±0.14SEM vs 
11.23µm/min±0.20SEM, p<0.0001, Figure 18 E). No difference could be detected in the 
meandering index between both groups (Figure 18 F). Overall, these data indicate increased 
recruitment and of TβSyn cells in response to increased antigen availability. To conclusively 
confirm the local reactivation of TβSyn cells, further experiments will be necessary; they will 
be addressed in the discussion. 
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Figure 18: Increasing local β-Synuclein availability via AAV transduction elevates TβSyn cell infiltration in 
the brain. 
Rats were neonatally transduced with an AAV expressing GFP or βSyn-GFP under a neuronal promoter and 
received TβSyn-mCherry transfer (5x106 per animal). Of note, for a more sensitive readout, a reduced 
number of T cells were transferred compared to other experiments. (A) Clinical score (bars) and relative 
weight change (lines) of AAV-βSyn-GFP rats (black bars/red line) or AAV-GFP controls (white bars/grey line) 
transferred with TβSyn-mCherry cells; n=7; Scores: 0 = No clinical symptoms; 0.5 = Reduced tail tone or 
partial tail paralysis; 1 = Tail paralysis; 2 = Gait disturbance/Ataxia; 3 = Hind limb paralysis; 4 = Tetraparesis; 
5 = Moribund. (B) In vivo TPLSM of an AAV-GFP rat brain day 4 p.t.; neurons (green) and TβSyn-mCherry 
cells (red); scale bar = 50µm. (C) 3D-reconstruction of TβSyn-mCherry cells (red) in close proximity to AAV-
GFP neurons (green); scale bar = 10µm. (D) Quantification of extravascular T cells per frame, taken from 
the first frame of every 30’ video. (E) Velocity and (F) meandering index and of TβSyn-mCherry cells 
observed over 30 minute periods. n=2, in two independent experiments 178 (AAV-βSyn-GFP) and 98 (AAV-
GFP) T cells were observed. (G) Brain slices from AAV-βSyn-GFP & (H) AAV-GFP control rats, d4 p.t., score 
1; AAV expression (green), TβSyn-mCherry cells (red) and DAPI-stained nuclei (blue), scale bars = 2mm; 
cut-outs show cortex & hippocampus, scale bars = 500µm. Statistical significance determined via Mann-
Whitney test, **p≤0.01, ****p≤0.0001. All data presented as mean±SEM. 
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IV.12. Spine density is reduced in TβSyn- but not TMBP-cell mediated ptEAE 
Given the presence of inflammatory infiltrates in the brain cortex, the neuronal integrity 
was examined. Indeed, as shown before (Figure 8), TβSyn cells were frequently found in direct 
proximity to cortical neurons, some of them seemed to directly interact with dendritic 
spines (Figure 18B & C, Figure 19 D-F). We therefore wondered if there were any detectable 
consequences on the cortical neurons themselves. In order to gain insight into possible 
changes within the cortex of EAE-affected rats, spine density analyses of the apical dendrites 
of cortical layer 2/3 neurons were performed at EAE peak. This method allows for the 
detection of morphological changes underlying synaptic transmission on a microscopic level 
that have also been implicated in MS pathology (Fiala et al., 2002; Magliozzi et al., 2010; 
Ksiazek-Winiarek et al., 2015). Changes in the density of dendritic spines occur very rapidly 
(Lendvai et al., 2000; Trachtenberg et al., 2002), therefore each experimental group (2-3 
repeated experiments per group) was accompanied with its individual set of healthy 
littermate controls. Interestingly, while spine density remained unchanged (p=0.9327) in 
rats at the peak of ptEAE induced by transfer of TMBP cells (2.30±0.10SEM spines/µm) versus 
control (2.26±0.08SEM spines/µm), the reduction of spine density in TβSyn cell ptEAE 
(1.42±0.05SEM spines/µm) compared to control (1.95±0.07SEM spines/µm) was highly 
significant (p<0.0001, Figure 19A & B). In an attempt to show a direct comparison of spine 
density in TβSyn and TMBP ptEAE, Figure 19 C shows all values transformed to be expressed as 
a percentage of the corresponding naïve littermate control. Spine density was reduced to 
74.60%±3.35SEM in TβSyn ptEAE (p=0.0210). In comparison, no change was detectable in 
TMBP ptEAE with 101.38%±3.20SEM change (p=0.8955). Notably, the observed effect did not 
persist after the acute EAE bout. In fact, spine density approaches control values with 
diminishing disease score (recovery) and can be assumed to completely normalize with 
disappearance of EAE pathology (data not shown).  
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Figure 19: Dendritic spines are reduced during peak TβSyn ptEAE, but not during TMBP ptEAE. 
Spine density on apical dendrites of cortical layer 2/3 neurons was (A) reduced in TβSyn ptEAE vs naïve 
littermate controls (1.42±0.05SEM vs 1.95±0.07SEM spines/µm, p<0.0001); n=7, 3 individual experiments). 
(B) Spine density remained unchanged in TMBP ptEAE (2.30±0.10SEM vs 2.26±0.08SEM spines/µm, 
p=0.9327); n=6, 2 individual experiments. (C) Shows the same data as relative percentages of the 
corresponding control (reduction to 74.60%±3.35SEM in TβSyn ptEAE, p=0.0210; no change in TMBP ptEAE 
with 101.38%±3.20SEM, p=0.8955). Apical dendrites of 6-8 cortical layer 2/3 neurons were analysed for 
each sample. Statistical significance determined via Mann-Whitney test. Data presented as mean±SEM. 
(D) Massive infiltration of TβSyn-GFP cells (green) around cortical layer 2 (Cl2) DiI-stained neurons (white); 
scale bar = 30µm. (E) Detail image of TβSyn-GFP cells around Cl2 dendrite. (F) 3D-reconstruction of (E) to 
highlight the extreme proximity of dendrite and T cell. (E&F) scale bars = 10µm. 
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IV.13. MRI as a tool for investigating EAE over time 
Longitudinal MRI was chosen as a method of observing the impact of neuronal EAE on brain 
and BBB. Both active and passive transfer EAE were investigated. The following parameters 
were evaluated: 
(1) Ventricular enlargement (Figure 20 A). It was described as an early indicator of EAE in 
mice (Lepore et al., 2013) and its occurrence has been linked to cortical atrophy in rat EAE 
(Tambalo et al., 2015). 
 
Figure 20: MRI analysis of ventricular enlargement and gadolinium enhancement. 
Representative images of a βSynTG(T/+) rat acquired during aEAE. (A) 3D reconstruction (frontal view) of 
the third (magenta) and lateral (turquoise/yellow) ventricles, before (PRE), during (PEAK) and after the 
course of EAE (POST). (B) Sagittal view of gadolinium enhancement in cortical meninges (upper panel, mid-
sagittal) and cortex (lower panel, ~0.5mm from mid-sagittal) before EAE induction and at disease onset; 
image acquired by Dr. Takashi Watanabe (Biomedizinische NMR Forschungs GmbH, MPI for biophysical 
Chemistry). 
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(2) Cortical thickness. Loss of brain volume is strongly associated with cognitive impairment 
in MS patients (reviewed by Vollmer et al., 2015). 
(3) Leakage of the BBB, measured by Gadolinium (Gad) enhancement (Figure 20 B). It has 
been shown to be linked to leukocyte infiltration and macrophage activation into the brain 
(Hawkins et al., 1990; Morrissey et al., 1996). 
Moreover, imaging of the eyes was included in this analysis, as inflammation was frequently 
detected here (not shown; Mor et al., 2003). 
 
 
IV.13.1. MRI in passive transfer EAE 
Animals were examined before induction, at the onset, at the peak of EAE, and 3-5 days 
after recovery. Intra-group analysis revealed a transient ventricular enlargement during the 
onset of EAE in TβSyn recipient rats (p=0.0154). This was, however, not significantly different 
from TMBP recipients (p=0.7765), who showed no significant overall changes (Figure 21 A). 
Cortical thickness remained unchanged in both groups over the entire observation period 
(Figure 21 B). Regarding the Gad enhancement caused by BBB leakage, the only site with a 
significant difference between the ptEAE groups were the meninges, where a substantial 
increase in signal intensity was found in TβSyn recipient rats at EAE onset (p=0.0046; Figure 
21 C). At this time point the intra-group analysis also revealed a highly significant, transient 
Gad enhancement within the TβSyn group (p=0.0002). Similarly, significantly increased Gad 
signals were detected at disease onset for both groups in the brainstem surrounding the 
area postrema and in the adjacent choroid plexus, a network of cells with a reduced 
tightness of the blood-CSF barrier, which was discussed as a possible entry site for T cells 
into the CNS (reviewed in Ransohoff and Engelhardt, 2012). In the white matter (corpus 
callosum) no changes could be detected in either group. 
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IV.13.2. MRI in active EAE 
Active EAE was induced in βSynTG(T/+) rats by immunization against βSyn and in MBPTG(T/+) 
rats using MBP (see IV.1). MRI was performed before induction, during EAE and 4-7 days 
after recovery. In many regards, the effects observed in ptEAE of βSyn-specific T cells 
appeared amplified in active EAE of βSynTG(T/+) rats. The increase in ventricular volume, 
 
Figure 21: Longitudinal MRI in neuronal and classical passive transfer EAE. 
Rats transferred with TβSyn (red) or TMBP (black) cells were examined before induction, at EAE onset, at 
peak, and 4-7 days after recovery. (A) Combined volume of lateral and third ventricles. (B) Change in 
cortical thickness. (C) Relative signal intensity of different brain areas and eye in Gad-enhanced T1-
weighted MRI. n=5; Statistical significance determined via repeated measures two-way ANOVA with 
Bonferroni’s multiple comparisons test for inter-group comparison (**p≤0.01) and Dunnett’s multiple 
comparisons test for intra-group analysis (#p≤0.05, ##p≤0.01, ###p≤0.001, ####p≤0.0001); hash mark 
colour indicates the group analysed (red TβSyn, black TMBP). 
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while again transient, was more than three-fold in some animals. Meanwhile, no increase 
was detectable in MBPTG(T/+) animals (p=0.0003, Figure 22 A). Indications of atrophy were 
found after recovery, where a significant decrease in cortical thickness was detectable by 
intra-group analysis in βSynTG(T/+) rats (p=0.0451). However, this reduction was not 
significant by inter-group comparison (Figure 22 B). 
 
Figure 22: Longitudinal MRI in βSyn-mediated active EAE in βSynTG(T/+) rats reveals transient 
ventricular enlargement and BBB disruption, as well as cortical atrophy. 
Rats actively immunized with βSyn (βSynTG(T/+) genotype, red, n=7) or MBP (MBPTG(T/+) genotype, 
black, n=5) were examined before induction, during EAE, and 4-7 days after recovery. (A) Combined 
volume of lateral and third ventricles. (B) Change in cortical thickness. (C) Relative signal intensity of 
different brain areas and eye in Gad-enhanced T1-weighted MRI. Statistical significance determined via 
repeated measures two-way ANOVA with Bonferroni’s multiple comparisons test for inter-group 
comparison (*p≤0.05, **p≤0.01, ***p≤0.001) and Dunnett’s multiple comparisons test for intra-group 
analysis (#p≤0.05, ##p≤0.01, ####p≤0.0001); hash mark colour indicates the group analysed (red βSyn, 
black MBP). 
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A transient breakdown of the BBB (i.e. Gad enhancement) was evident not just in the 
meninges (p=0.0015), but also in the parietal cortex (p=0.0441) during EAE in βSynTG(T/+) but 
not MBPTG(T/+) animals (Figure 22 C). As in ptEAE, no significant change was detected in the 
corpus callosum. MBPTG(T/+) rats further showed Gad enhancement in brain stem, 
cerebellum and also the hippocampus. In inter-group analyses, these values were only 
significant in the brain stem (p=0.0448). 
Interestingly, the eyes were also strongly affected in aEAE of βSynTG(T/+) rats. Strong Gad 
enhancement, indicative of uveitis, was detected in the eyes of most rats (p=0.0015; Figure 
22 C). Virtually no βSynTG(T/+) rat examined by MRI was free of morphological changes in the 
eye, while in MBPTG(T/+) rats the eyes were not affected (not shown). 
 
IV.14. Repeated inflammatory bouts aggravate EAE-induced changes in the brain 
So far, MRI and histological data indicated that a single inflammatory attack induces 
transitory neuronal damage. In MS, a strong connection was drawn between meningeal 
inflammation, neuronal pathology and disability (Magliozzi et al., 2010). Interestingly, we 
discovered that heterozygous receptor-transgenic βSynTG(T/+) rats can be repeatedly 
transferred with TβSynTG(T/T) cells, each time resulting in EAE development. This provides a 
singular opportunity for studying the consequence of repeated CNS grey matter 
inflammations solely incited by encephalitogenic T-cell transfer. Drawing parallels to MS, the 
effects of repeated inflammatory bouts on the CNS tissue were examined. Therefore, 
βSynTG(T/+) rats were transferred with either TβSynTG(T/T) (EAE) or TOVA (control) cells, for four 
times every 15 days. βSynTG(T/+) rats responded with a severe bout of atypical EAE to every 
transfer of TβSynTG(T/T) cells, followed by apparent complete remission of clinical symptoms; 
TOVA-GFP recipients remained healthy (Figure 23 A). There was no significant difference 
between EAE and control after the first EAE bout (p=0.0751), whereas a highly significant 
reduction in cortical thickness was detected four days (p<0.0001) and even 18 days after 
recovery from the last EAE (p=0.0003, Figure 23 B). No such change was detected at any 
point in the corpus callosum (Figure 23 C), underlining the cortical grey matter as the actual 
target of the observed effects. MRI examination revealed prominent ventricular 
enlargement in EAE animals during the first disease episode (p<0.0001), receding within 3 
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days post recovery. After the fourth bout of EAE, this enlargement was again detected 
(p=0.0097), but it did not recede completely after four (p=0.0001) and even 18 days post 
recovery (p=0.0077), indicative of an irreversible change in brain structure (Figure 23 D). We 
subsequently measured rotarod performance in rats which had suffered multiple episodes 
of EAE, but found no evidence of motor deficits (Figure 23 E). Additionally, no changes in 
dendritic spine density were found six weeks after the last EAE bout (Figure 23 F), indicating 
compensatory or regenerative mechanisms in the remaining neurons. 
Analysis of Gadolinium enhancement during the first and fourth EAE episode revealed a 
highly significant BBB disruption in the cortical meninges, all examined cortical areas 
(occipital, parietal, frontal and temporal), as well as the superior and inferior colliculi (Figure 
23 G). The choroid plexus and the epiphysis were also affected, but not the area postrema, 
hippocampus, nor the corpus callosum, cerebellum, brainstem or eyes. This correlated well 
with the observed infiltration pattern of TβSyn cells (Figure 8). Interestingly, Gadolinium 
enhancement trended to decline with repeated EAE incidences, hinting at potential 
compensatory mechanisms which strengthened BBB integrity after multiple inflammatory 
events.  
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Figure 23: Repeated inflammation aggravates EAE-associated changes in the brain. 
βSynTG(T/+) rats transferred four times with TβSynTG(T/T) (red) or TOVA (black) cells were examined over the 
course of multiple EAE bouts. (A) Clinical score (bars) and weight change (lines) presented as mean±SEM. 
Scores: 1* = Ataxia, occasional twitches and scratching; 2* = Frequent twitches and scratching, slight 
imbalance; 2.5*= Pronounced imbalance; 3* = Spastic paresis of hind limbs; 4* = Tetraparesis; 5* = 
Moribund. (B) Change in cortical thickness, (C) change of corpus callosum thickness before first EAE, 3d 
post recovery of first EAE and 4d as well as 18d post recovery of fourth EAE. (D) Combined volume of 
lateral and third ventricles before, during and after the first as well as fourth EAE. (E) Rotarod performance 
2d after recovery from the fourth EAE, presented as mean±SEM. (F) Spine density on apical dendrites of 
neurons in cortical layer 2/3, 6 weeks after recovery from the fourth EAE. (G) Relative signal intensity of 
different brain areas and eye in Gad-enhanced T1-weighted MRI. Sample sizes indicated in graphs. 
Statistical significance determined via repeated measures two-way ANOVA with Bonferroni’s multiple 
comparisons test (*p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001). 
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V. Discussion 
V.1. Invasion of neuron-specific T cells into the grey matter 
The goal of this thesis was to characterize a grey matter EAE model using βSyn as the 
primary trigger of immunological action. While the use of βSyn as antigen to induce EAE is 
not novel, all published studies rely either on transferring a significantly higher number of 
T cells (Mor et al., 2003) or pre-treating recipients by irradiation or injecting immunized rats 
with cyclophosphamide or PTX (Mor & Cohen, 2006; Kela-Madar et al., 2009). More 
importantly, these studies focused on the infiltration of TβSyn cells in spinal cord and/or uvea. 
Although an infiltration of mononuclear cells into the cerebral cortex was described and 
speculations about cortical involvement were made (Mor et al., 2003; Mor & Cohen, 2006), 
TβSyn-cell infiltration into the brain was never specifically addressed. In none of these 
previous studies the pathogenic T cells were tracked. Finally, from a clinical point of view, 
the occurrence of atypical symptoms was not observed. It should be mentioned that these 
atypical clinical signs were more frequently observed in ptEAE induced by TβSynTG cells from 
T-cell receptor-transgenic rats. In the wild-type rats the classical EAE disease type 
dominated. 
This thesis demonstrates that 1) pathogenic TβSyn cells can be reliably generated and used 
for inducing transfer EAE and 2) active EAE can be reproducibly induced in receptor-
transgenic rats. In both cases, no additional treatment with pertussis toxin or 
cyclophosphamide was required. Taking advantage of our transfer model using GFP-tagged 
cells, we could further track and functionally characterize the encephalitogenic TβSyn cells on 
their way into the cortex and finally describe the consequences of grey matter infiltration by 
neuron-specific T cells. 
One of the most intriguing findings in this project was the discovery of the occurrence of 
atypical symptoms in many of the TβSynTG(T/+) and all of the TβSynTG(T/T) recipients. While 
immunization with βSyn constantly led to the development of the classical EAE symptoms of 
ascending paralysis, transfer with in vitro activated TβSyn cells of wild-type origin resulted in 
only a moderate fraction of atypical cases. Furthermore, these cases manifested themselves 
in front limb paralysis or hemiparesis (Schlosser, 2013). While still only poorly characterized, 
the symptoms observed here seemed to rather affect the rats’ sense of balance, fine-motor 
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control in all four limbs as well as sensory or sensorimotor pathways resulting in scratching 
behaviour and twitching or jerking movements. Upon TβSynTG(T/T) cell transfer, these 
symptoms became so pronounced they were reminiscent of some of the symptoms 
described in rodent epilepsy models (Curia et al., 2008). 
While the induction of active EAE is always dependent on boosting the innate immune 
system (e.g. by the use of CFA, reviewed by Libbey & Fujinami, 2011), it is crucial to be able 
to forgo further interference with the immune system or BBB, especially when changes in 
BBB permeability are investigated in response to CNS inflammation. PTX strongly affects the 
immune system and has been shown to transiently increase BBB permeability in rodents 
and human cultured endothelial cells (Brabb et al., 1997; Kerfoot et al., 2004; Kügler et al., 
2007). It further blocks chemokine receptors such as CXCR4 and CCR5, activates the TCR 
signalling cascade and subsequently inhibits CXCL12-mediated chemotaxis (Witvliet et al., 
1992; Schneider et al., 2009). Cyclophosphamide was shown to deplete CD4+CD25+ 
regulatory T cells (Ghiringhelli et al., 2004) and, although with contradicting results, has 
been used in the treatment of MS (Awad & Stüve, 2009). Immunization of βSynTG(T/+) rats 
with the βSyn93-111 peptide and CFA does not require any further steps to reliably induce 
active EAE (Figure 5). As this induction is stable up to an age of 6 months and probably well 
beyond (Figure 6), this model might be an interesting candidate for the research into 
autoimmunity in aged rats, an approach that has been argued to increase translatability of 
rodent data to humans (Jackson et al., 2017). Why active neuronal EAE can only be induced 
in heterozygous βSynTG rats remains unclear. As T cells from draining lymph nodes of 
immunized animals could be isolated and used in the generation of pathogenic cell lines, the 
priming phase of these T cells did not seem to be affected. Possibly, a strict control of self-
tolerance against neuronal antigens in these animals prevented EAE development. To test 
this hypothesis, cyclophosphamide could be used to pre-treat these animals before EAE 
induction, in analogy to the approach used by Kela-Madar and colleagues (Kela-Madar et al., 
2009). 
Apart from the accelerated disease course of EAE induced via passive transfer compared to 
active immunization (Figure 7), another obvious advantage of this approach is that by using 
retroviral transduction, antigen-specific T cells can be modified to express genes for 
fluorescent proteins and traced on their way to and through the CNS (Flügel et al., 1999, 
Discussion  62 
2007). Amongst others, this approach allowed the first visualization of the in vivo entry of 
TMBP cells into the SC and their infiltration into the CSF via the leptomeninges (Bartholomäus 
et al., 2009; Schläger et al., 2016). Utilising this method and building on the work of Mor and 
colleagues (Mor et al., 2003), who discovered the encephalitogenic potential of TβSyn cells, it 
could be shown that these cells preferentially invade the grey matter of the brain, an area in 
which TMBP cells are rarely found (Figure 8 & 9; Schlosser, 2013). To investigate if intrinsic 
properties of T cells in the pre-clinical phase would justify their different homing, three 
experimental approaches were chosen: (1) TPLSM of T cells at the CNS vascular bed, (2) 
signalling-blockage of selected integrins and chemokines and (3) transcriptome analysis via 
next generation sequencing.  
(1) For the first approach, the intraluminal crawling behaviour of TβSyn, TMBP as well as CNS-
ignorant TOVA cells was examined in pial vessels of brain and SC just before EAE onset (Figure 
10). Overall, no qualitative differences seemed to exist between T cells of different antigen-
specificities, as they displayed the same rolling and crawling phenotypes. However, a 
quantitative difference was detected, most evident in the percentage to which cells crawled 
inside the CNS vessels. Correlating with the amount of T cell infiltration and the 
inflammation state of the surrounding tissue, TMBP cells, which almost exclusively infiltrated 
the SC, preferentially crawled in SC vessels. In the brain, were only small numbers of TMBP 
cells were detected, they were mainly found to be rolling. On the other hand, TβSyn cells 
preferentially crawled in both compartments, matching their infiltration profile in both brain 
and SC. This is in line with the observation of Bartholomäus and colleagues, who artificially 
introduced OVA as an antigen into the CNS and found a subsequent inflammation caused by 
local re-activation of usually CNS-ignorant TOVA cells. This inflammation in turn had a marked 
effect on the intraluminal crawling behaviour of TOVA cells (Bartholomäus et al., 2009). 
Interestingly, we found TOVA cells crawling in a reduced numbers in brain vessels compared 
to the SC. As these T cell recognize an irrelevant antigen, this finding came as a surprise. 
However, as the same discrepancy was observed for CD11b+ monocytes in naïve rats, we 
hypothesized that differences between brain and SC endothelium or blood flow (e.g. 
Nyström & Norlén, 1983; Wilhelm et al., 2016) might influence the crawling behaviour of 
patrolling cells, but that this effect was leveraged under inflammatory conditions.  
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 (2) The expression of integrins and chemokine receptors is highly similar between TMBP and 
TβSyn cells (Figure 15), as are their in vitro responses to chemoattractants (Schlosser, 2013). 
In Lewis rat EAE, capture, adhesion, crawling and the subsequent transmigration of TMBP 
cells at the SC vasculature can be inhibited by treatment with VLA-4-blocking antibody, 
while no effect of blocking LFA-1 is observed. Subsequently, preventive treatment with 
αVLA-4, but not αLFA-1 antibodies diminishes TMBP cell mediated EAE development 
(Bartholomäus et al., 2009). The effects of blocking these integrins in TβSyn cells in the brain 
vasculature were comparable: αVLA-4 treatment was effective in blocking TβSyn cell adhesion 
and crawling, as well as EAE development and strongly reduced CNS infiltration (Figure 12). 
Blocking of LFA-1 only mildly interfered with TβSyn cell adhesion, but had no further apparent 
effect; neither did it prevent EAE development (Figure 13). Of note, in other EAE models 
LFA-1 was shown to be essential for adhesion and subsequent transmigration (Vajkoczy et 
al., 2001). However, in MS patients, blockage of VLA-4 (by the drug Natalizumab), but not of 
LFA-1, was shown efficacious (Lublin & the Hu23F2G MS Study Group, 1999; Goldenberg, 
2012). 
Chemokine receptor CXCR3 is highly expressed in TβSyn cells and seems important for BBB 
transmigration as well as pathogenicity of Th1/17 cells (Lee et al., 2012; Schlosser, 2013; Hu 
et al., 2017). Its influence on intraluminal crawling of TβSyn cells in the brain, however, was 
negligible (Figure 14). CNS infiltration was not addressed here, but it remains plausible to 
assume that blocking CXCR3 could impair EAE development by inhibiting BBB transmigration, 
as it was demonstrated in murine TMBP cell ptEAE (Sporici & Issekutz, 2010). Overall, the 
findings described here seem parallel to observations made for TMBP cells, further 
underlining functional similarity between T cell lines of different antigen-specificities. 
(3) Perhaps the most direct confirmation for the similarity between circulating TβSyn and TMBP 
cells came from our transcriptome analyses. TMBP cells isolated from blood showed little to 
no signs of activation (Schläger et al., 2016). Compared to these, virtually no differences 
were found in TβSyn cells taken from blood regarding chief cytokines, chemokine and 
cytokine receptors, cell adhesion and motility molecules as well as transcription factors. 
Merely the expression of IL2ra was found moderately reduced in TβSyn cells. IL2ra (also 
known as CD25) is an important growth-factor for T cells, and IL-2 signalling restricts Th17 
development and the main target of the MS drug Daclizumab (Morgan et al., 1976; 
Discussion  64 
Laurence et al., 2007; Zhang et al., 2014). Thus, the relative down-regulation of IL2ra might 
have some functional relevance, but the NGS analysis overall underlined the similarities 
between neuron- and myelin-specific T cells preceding re-activation inside the CNS. It has 
been hypothesized that signalling-molecule expression profiles guide effector T-cells’ 
infiltration into different CNS compartments. While Th17 cells were suggested to enter the 
brain via the CCR6-CCL20 axis, Th1 cells would enter the SC via the meninges in a CXCR3- 
and VLA-4-mediated fashion (Stromnes et al., 2008; Reboldi et al., 2009; Rothhammer et al., 
2016). In our model, this could be reasonably excluded, as expression profiles as well as the 
response to receptor-blockage did not meaningfully differ between TβSyn and TMBP cells and 
no specific enrichment of either Th1 or Th17 phenotype in the target tissue was detected 
(Figure 16).  
Our data demonstrate that antigen-specificities or expression profiles cannot explain T cell 
homing into different target tissues. Based on this insight, we hypothesized that T cells 
which routinely patrol the CNS (Figure 10; Bartholomäus et al., 2009; Reboldi et al., 2009; 
Odoardi et al., 2012) become re-activated in situ (Kawakami et al., 2004; Lodygin et al., 2013) 
and initiate a self-perpetuating process: local re-activation leads to the production of pro-
inflammatory cytokines, leading in turn to the recruitment of more T cells, monocytes and 
microglia activation, in turn causing more inflammation and recruitment, finally resulting in 
EAE development. Again, three sets of data were acquired to support this hypothesis: (1) 
observation of TβSyn cell motility in the brain parenchyma, (2) NGS sequencing and (3) an 
AAV-mediated increase in local antigen availability. 
(1) The motility characteristics of TβSyn cells argued for the occurrence of local re-activation 
(Figure 16). TPLSM revealed that TβSyn cells scanned the brain parenchyma freely and 
thoroughly. An increase in arrested T-cell number, in comparison with the number detected 
in the pre-clinical phase, indicated a heightened frequency of T-cell-APC-interactions. TMBP 
cells show very similar motility patterns while being re-activated by interacting with APCs in 
the SC leptomeninges (Lodygin et al., 2013) and it seems in turn reasonable to assume an 
identical process to take place for TβSyn cells within the brain parenchyma. 
(2) NGS transcriptome analysis of brain-derived TβSyn cells (Figure 17) revealed an up-
regulation of the IFNγ and IL-17 signalling pathways. These increases were likely caused by 
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local re-activation, as they were not observable in blood-derived cells. This is in line with the 
previously described up-regulation of CD25 and OX40 detected via intracellular staining for 
ex vivo, brain-derived TβSyn cells (Schlosser, 2013). TMBP cells extracted from the SC show a 
highly similar expression profile (Bartholomäus et al., 2009; Schläger et al., 2016) and have 
been demonstrated to undergo local re-activation in the SC leptomeninges and parenchyma 
(Lodygin et al., 2013). 
 (3) We argued that increased antigen availability should lead to more frequent APC-
mediated antigen-encounters, consequently speeding up the EAE-induction cycle. Indeed, 
locally increased antigen availability had a marked effect on the infiltration and motility of 
TβSyn cells (Figure 18). A 3-fold increase in the number of TβSyn cells was detected in the 
brains of AAV-βSyn-GFP rats, animals where a subpopulation of neurons over-expressed 
βSyn. Supportive of our hypothesis, local overexpression seemed to even recruit TβSyn cells 
to areas that are otherwise only sparsely infiltrated, like the hippocampus. This is again 
similar to the observations of Bartholomäus and colleagues, where TOVA cells have been 
shown to infiltrate the CNS and initiate inflammation when their antigen was made 
artificially available (Bartholomäus et al., 2009). Additionally, the velocity of TβSyn cells was 
drastically reduced in AAV-βSyn-GFP rats, indicative of an increased occurrence of antigen-
recognition (Flügel et al., 2007; Odoardi et al., 2007).  
Altogether, these observations are supportive of our hypothesis. However, in order to 
provide conclusive proof that TβSyn cells are locally re-activated, leading in turn to an 
increase in T-cell recruitment, further experiments will be necessary. One strategy currently 
pursued is the creation of βSyn-specific T-cell lines expressing fluorescently tagged NFAT. As 
it has been demonstrated for TMBP cells in the SC, these cells would allow the visualization of 
TβSyn-cell re-activation in situ (Lodygin et al., 2013), exploiting the relocation of NFAT to the 
nucleus in response to antigen-stimulation, in turn regulating gene expression for T-cell 
activation (Shaw et al., 1988). Furthermore, rats could be treated with FK506 just before 
EAE onset, as FK506 leads to a re-localization of NFAT into the cytosol, inhibiting T-cell 
(re-)activation (Schreiber & Crabtree, 1992). Alternatively, Ox6 antibodies could be used to 
block the interaction of T cells and MHC-II molecules within the brain (McMaster & Williams, 
1979).  
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V.2. The brain as a target of autoimmune attack: linking MS and EAE grey 
matter pathology 
Grey matter lesions are frequent, often occur already early in the MS course and are 
strongly linked to disability (Peterson et al., 2001; Hulst & Geurts, 2011; Geurts et al., 2012; 
Calabrese et al., 2013; Schlaeger et al., 2014; Calabrese, Reynolds, et al., 2015). Furthermore, 
grey matter lesions have been shown to contain activated microglia and infiltrated immune 
cells, suggesting the involvement of these cells as mediators of neurodegeneration 
(Lucchinetti et al., 2011). Meningeal inflammation was further associated with neuronal loss 
and cortical grey matter lesions. These have, in turn, been correlated with the progression 
of clinical decline in (both secondary and primary) progressive MS patients (Howell et al., 
2011; Choi et al., 2012). Diffuse inflammatory patterns, independent of focal lesions, have 
also been postulated to induce neuronal pathology (Magliozzi et al., 2010; Calabrese, 
Magliozzi, et al., 2015). This implies an immune cell-mediated, inflammation-driven cortical 
neurodegeneration in MS, which is at least to a certain extent independent of 
demyelination. In a post-mortem MS study, dendritic spines of cortical neurons have been 
found to be significantly reduced, independent of lesion-location (Jürgens et al., 2016). As 
dendritic spines are of central importance for synaptic transmission, it is likely that this loss 
contributes to the cognitive impairment seen in MS patients (Chiaravalloti & DeLuca, 2008; 
Grienberger et al., 2015). This so called synaptopathy is today considered a pivotal element 
in MS pathology (Centonze et al., 2010; Mandolesi et al., 2015). In chronic-progressive EAE 
models, a reduction in dendritic spine density was found in the striatum of mice (Centonze 
et al., 2009) and cortical layer 4 neurons of Dark Agouty rats, accompanied by grey matter 
atrophy (Tambalo et al., 2015). Here, we demonstrate that a reduction in cortical (layer 2 & 
3) spine density can be acutely induced by the transfer of neuron-, but not myelin-specific T 
cells (Figure 19). This provides a direct link between local inflammation and spine-density 
reduction. Furthermore, it underlines the relevance of inflammation for the generation of 
grey matter pathology; supporting the notion that neurodegeneration could be 
independent of the location of cortical demyelinating lesions and rather dependent on 
inflammation. Both IFNγ and TNFα have been shown to mediate inflammation-dependent 
dendritic spine loss, identifying Th1 cells and activated microglia as potential candidates for 
(preventive) treatment approaches (Centonze et al., 2009; Kreutzfeldt et al., 2013; Yang et 
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al., 2013). Macrophage/microglia activation and T-cell infiltration also correlate with BBB 
breakdown in SC, brainstem and cerebellum in the classical myelin EAE model in mice and is 
revealed by Gadolinium enhancement (Hawkins et al., 1990; Morrissey et al., 1996; Nessler 
et al., 2007). The use of Gadolinium as a contrast agent in studying MS lesions has long been 
established (Grossman et al., 1986). Exploiting this approach, we found Gadolinium to be 
selectively enhanced in the cortical meninges of TβSyn-cell induced, but not TMBP-cell 
mediated passive transfer EAE (Figure 21). In βSyn active EAE, Gadolinium enhancement 
was even more pronounced, extending into the parietal cortex (Figure 21). These findings 
are in line with the observed massive infiltration of TβSyn cells into meninges and cortex 
(Figure 8) and the reduction in spine density in the superficial layers (Figure 19). Our 
observation that ventricular volume transiently increases during EAE could be caused by an 
inflammation-dependent surge in CSF production by the choroid plexus (Karimy et al., 2017), 
indicative of inflammatory damage and cortical atrophy (Lepore et al., 2013; Tambalo et al., 
2015), or both. Cortical atrophy is considered a hallmark of MS and strongly associated with 
clinical disability (De Stefano et al., 2003; Calabrese et al., 2009; Calabrese, Rinaldi, et al., 
2010; Calabrese, Rocca, et al., 2010; Vollmer, Huynh, et al., 2015; Vollmer, Signorovitch, et 
al., 2015). While in ptEAE no change was apparent, we observed a significant reduction in 
cortical thickness in the wake of βSyn active EAE (Figure 22), further recommending the 
βSyn neuronal EAE model for the investigation of grey matter pathology. 
Another exceptional aspect of our model is the possibility of inducing multiple independent 
bouts of inflammation via the repeated transfer of TβSynTG(T/T) cells to βSynTG(T/+) recipients  
(Figure 23). Tambalo and colleagues describe long-term cortical atrophy and synaptopathy 
in Dark Agouty rat EAE after immunization with CNS homogenate, but these animals never 
show full remission of clinical symptoms, suggestive of chronic inflammation (Tambalo et al., 
2015). Attempts to induce lasting grey matter lesions by repeated, discrete inflammatory 
episodes have so far been unsuccessful: repeated cortical injection of a combination of 
TNFα and IFNγ only leads to transient lesion formation and is leveraged by the regenerative 
capacity of oligodendroglia precursor cells (Merkler, Ernsting, et al., 2006; Rodriguez et al., 
2014). Another approach combines TMBP-cell transfer and anti-MOG antibody-injection, 
resulting in demyelinating lesions which persist for at least 60 days in the SC white matter, 
however no grey matter pathology is observed (Linington et al., 1992). Similarly, the 
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combination of two inflammatory stimuli might lead to a persisting susceptibility to EAE in 
our model: while Linington and colleagues combined activated T cells with antibodies, a 
possible low level of persisting inflammation caused by the presence of auto-reactive, βSyn-
specific T cells or self-antibodies in combination with the transfer of fresh, activated cells 
might be the mediator in our model. The observation of lasting ventricular enlargement and 
severe, persistent, cortical atrophy found after multiple inflammatory bouts reinforces the 
connection between meningeal inflammation and neuronal degeneration and argues 
against the hypothesis that neurodegeneration and inflammation can be considered 
separate processes (e.g. Hutchinson, 2015; Louapre & Lubetzki, 2015).  
It will be interesting to see what more sensitive readouts will unveil about atrophy and 
higher brain function in our model (e.g. using the 5-choice serial reaction time task; Robbins, 
2002). Finally, an on-going morphological analysis revealed strong signs of degeneration in 
cortical neurons (not shown). In face of the absence of dendritic spine reduction, this 
observation might suggest intact regenerative capacities in the persisting neurons. Taking 
this into consideration, our model could help to better understand which pathways critically 
contribute to the neuronal degeneration underlying MS pathology and to investigate 
potential neuroprotective approaches (Friese et al., 2014).  
As discussed in the introduction, other rodent EAE models exist that evoke some aspects of 
grey matter pathology, but they either target myelin or astrocytes, but not neuronal 
antigens (Kojima et al., 1994; Storch et al., 2006), or target neuronal antigens without 
eliciting clear grey matter pathology in the brain (Huizinga et al., 2007, 2008). Taken 
together, the βSyn neuronal EAE model examined here combines three major hallmarks of 
grey matter MS pathology, i.e. meningeal inflammation, synaptopathy and cortical atrophy, 
by targeting a single neuronal antigen. To my knowledge, it is the only rodent model to do 
so and will provide a useful tool for studying the underlying mechanisms and determining 
potential treatment routes.   
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VI. Summary 
In the present thesis I demonstrated that pathogenic TβSyn cells of wild-type and receptor-
transgenic origins could be reliably generated and used for inducing passive transfer EAE; 
active EAE could be reproducibly induced in receptor-transgenic rats. Both inductions were 
possible without pre-treatment of recipient animals with pertussis toxin or 
cyclophosphamide. I additionally described the possibility to induce multiple independent 
bouts of inflammation and EAE by repeated transfer of TβSynTG(T/T) cells into βSynTG(T/+) 
recipients. 
Additionally, I presented evidence supporting the hypothesis that local re-activation, not 
cell-intrinsic properties, determined T-cell homing into the target CNS tissue. Motility and 
gene-expression were highly similar between TβSyn and TMBP cells prior to CNS infiltration. 
Intravascular crawling of TβSyn cells was found to be dependent on VLA-4, but not LFA-1 or 
CXCR3, as it has been previously described for TMBP-cell mediated EAE in the Lewis rat. 
Subsequently, the motility parameters and gene expression of TβSyn cells in the brain 
suggested an activated state of these cells and resembled the parameters described for 
locally re-activated TMBP cells located inside the SC. Local overexpression of the βSyn antigen 
led to an increased recruitment of TβSyn cells into the cortex, further emphasizing the 
importance of antigen-recognition for T-cell homing. 
Addressing the consequence of T-cell mediated inflammation in the brain, I demonstrated 
that transfer of TβSyn cells, but not of TMBP cells, mediated a transient reduction in synaptic 
spine density on cortical neurons, thereby providing a direct link between local 
inflammation and alterations in neuronal connectivity. Finally, I showed that active EAE as 
well as the repeated transfer of TβSynTG(T/T) cells induced neurodegeneration in βSynTG(T/+) 
rats, indicated by cortical atrophy. 
Taken together, several hallmarks of MS could be reproduced here by targeting the 
neuronal antigen βSyn, namely meningeal inflammation, synaptopathy and cortical atrophy. 
These observations recommend the βSyn neuronal EAE model as a suitable model for 
immune cell-mediated, inflammation-driven cortical neurodegeneration in MS and further 
underline the importance of researching the neuronal and grey matter aspects of the 
disease.  
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VIII. Abbreviations 
aEAE  active Experimental Autoimmune Encephalomyelitis 
APC  Antigen Presenting Cell 
BBB  Blood-Brain Barrier 
CCR5  C-C Chemokine Receptor type 5 
CFA  Complete Freund’s Adjuvant 
CIS  Clinically Isolated Syndrome 
CNS  Central Nervous System 
ConA  Concanavalin A 
CXCL12 C-X-C motif Chemokine Ligand 12 
CXCR3  C-X-C Chemokine Receptor type 3 
CXCR4  C-X-C Chemokine Receptor Type 4 
EAE  Experimental Autoimmune Encephalomyelitis 
EH  Eagles HEPES 
FACS  Fluorescence-Activated Cell Sorting 
FCS  Fetal Calf Serum 
Gad  Gadolinium (here: Gadobutrol-solution/Gadovist®) 
GFP  Green Fluorescent Protein 
GWAS  Genome-wide Association Studies 
i.t.  intrathecal 
i.v.  intravenous 
ICAM  Intracellular Adhesion Molecule 
IFNγ  interferon gamma 
LFA-1  Lymphocyte function-associated antigen 1 
MADCAM1 Mucosal vascular Addressin Cell-Adhesion Molecule 1 
MBP  Myelin Basic Protein 
Abbreviations  85 
MBPTG MBP specific receptor-transgenic rat line 
MHC class II Class II Major Histocompatibility Complex 
MOG  Myelin Oligodendrocyte Protein 
MRI  Magnetic Resonance Imaging 
MS  Multiple Sclerosis 
NFAT  Nuclear Factor of Activated T cells 
NGS  Next Generation Sequencing 
OVA  Ovalbumin 
PBMC  Peripheral blood mononuclear cell 
p.r.  post recovery 
p.t.  post transfer 
PFA  Paraformaldehyde 
PLP  Proteolipid Protein 
PPMS  Primary Progressive Multiple Sclerosis 
ptEAE  passive transfer Experimental Autoimmune Encephalomyelitis 
qPCR  quantitative real-time Polymerase Chain Reaction 
RM  Re-stimulation Medium 
ROI  Region Of Interest 
RRMS  Relapsing Remitting Multiple Sclerosis 
SC  Spinal Cord 
SI  Signal Intensity 
SPMS  Secondary Progressive Multiple Sclerosis 
TAG-1  Contactin-2/Transiently expressed Axonal Glycoprotein 1 
TCM  T-Cell Medium 
TCR  T-cell Receptor 
TMBP cell MBP-specific T cell 
Abbreviations  86 
TNFα  Tumour Necrosis Factor alpha 
TPLSM  Two-Photon Laser Scanning Microscopy 
TβSyn cell β-Synuclein93-111 peptide-specific T cell 
VCAM  Vascular Cell Adhesion Molecule 
VLA-4  Very Late Antigen-4 
βSyn  β-Synuclein93-111 peptide 
βSynTG β-Synuclein93-111 peptide-specific receptor-transgenic rat line  
Acknowledgements  87 
IX. Acknowledgements 
I wish to express my sincerest gratitude to Prof. Alexander Flügel for his supervision and 
inspiration during the entire time of my PhD studies and for giving me the opportunity to 
work on this fascinating project. I further want to thank my supervisor Prof. Francesca 
Odoardi for her invaluable support, guidance and encouragement. 
My gratitude goes to Prof. Holger Reichardt and Prof. Jürgen Wienands who supported me 
as members of my thesis advisory committee, as well as Prof. Hannelore Ehrenreich, Prof. 
Wolfgang Brück and Dr. Sebastian Kügler for agreeing to be part of my examination board. 
I would like to thank Dr. Henrike Fischer and Dr. Dmitry Lodygin for creating the receptor-
transgenic rat lines and their constant advice and support. 
For all their time and expertise, their advice and kindness during our collaboration, I would 
like to thank Dr. Marta Zagrebelsky-Holz and Dr. Takashi Watanabe.  
I am very grateful to Adriane Stas, Angelika Mönnich, Simon Mole and Simone Hamann for 
their outstanding support and technical assistance. 
Finally, I want to thank everyone else who supported me during the course of my PhD: 
Angelika, Lothar, Lisa and Dr. Wolfgang Hermann for their unfaltering love and support, not 
only during the last years, but during my entire life; Jenni, Stefan, Nico, Martin, Hendrik, 
Sönke and Verena, who I could always rely on; Judith, Leon, Michael, Basti, Henrike², 
Arianna, Phteven, César, Addi, Guiseppe and all other members of the IMSF for being not 
only colleagues, but friends.  
Declaration  88 
X. Declaration 
 
I hereby declare that I prepared the doctoral thesis “Analysis of autoimmune lesions in grey 
matter” on my own and with no other sources and aids than quoted.  
 
 
Moritz Hermann 
Göttingen, December 2017 
 
  
